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Despite the significant progress made in the treatment of cancer, it remains 
one of the leading causes of death worldwide with about 10 million estimated 
cancer deaths in 2020 (Sung et al. 2021). To improve the safety and off-
target effects, as well as the effectiveness of cancer therapies, research in 
novel cancer therapeutics is fundamental. 
Cancer immunotherapy includes a variety of strategies to activate and boost 
a patient's own immune system to detect and destroy cancer cells. In this 
context, oncolytic virotherapy is an emerging branch of cancer treatment, 
which takes advantage of the capacity of natural or genetically modified 
viruses to selectively replicate in cancer cells, leading to tumor cell lysis. 
Many different viruses have been tested as oncolytic viruses, including 
vaccinia virus (VACV), which provides several advantages such as a fast 
and lytic replication, an extensive safety record in humans and a high 
capacity to harbor transgenes. Importantly, replication of VACV within the 
tumor can result in cellular immune responses targeting relevant tumor 
antigens and in a transient overcoming of the localized immune suppression 
in the tumor microenvironment. However, this mechanism demonstrated in 
clinical trials to be not efficient enough for activating effective antitumor 
immune responses in a wide number of tumor patients. 
The goal of this study was to investigate novel modifications introduced to 
oncolytic VACV to enhance their capacity to induce potent anti-tumor 
immune responses. As robust antitumor cytotoxic T-cell responses 
demonstrated to be key for the successful treatment of cancer, and 
activation of the TLR3-IRF3 pathway directly correlates with activation of 
such immunities, we constructed a panel of oncolytic VACV combining 
deletions in genes involved in the inhibition of IRF3 pathway activation. We 
evaluated the replication capacity in cancer cells, their ability to induce anti-
tumor T cell response, and their antitumor efficacy in mouse tumor models. 
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II LITERATURE REVIEW 
1. Cancer and the immune system 
Cancer is characterized by the accumulation of cells with genetic defects in 
regulatory circuits controlling cell proliferation and homeostasis, leading to 
uncontrollable proliferation. However, this is not the only feature that 
distinguish normal cells and cancer cells. Hanahan and Weinberg described 
in 2000 six “hallmarks of cancer”, including resisting cell death, evading 
growth suppressors, sustaining proliferative signaling, enabling replicative 
immortality, induction of angiogenesis, and activation of invasion and 
metastasis (Hanahan and Weinberg 2000). With new developments in the 
understanding of the biology of cancer, they added two emerging hallmarks 
a decade later: reprogramming of cellular energy metabolism to support 
excessive cellular proliferation and active evasion by cancer cells from the 
immune system to avoid destruction (Hanahan and Weinberg 2011).  
Since Paul Ehrlich first proposed the idea that the development of cancerous 
cells in our body can be suppressed by the immune system (Ehrlich 1909), 
the role of the immune system regarding cancer was controversially 
discussed for decades until the role of Interferon-γ (IFN-γ) in promoting 
immunologically induced rejection of transplanted tumors was described 
(Dighe et al. 1994). When it was also described that mice lacking an adaptive 
immunity were more susceptible towards carcinogen-induced or 
spontaneous tumor formation, the immune surveillance hypothesis 
postulated by Sir Frank Mac Farlane Burnet was reinforced. Such 
hypothesis, postulated that tumor cell-specific neo-antigens could provoke 
an effective immunologic reaction that would lead to regression of the tumor 
(Kaplan et al. 1998; Shankaran et al. 2001; Burnet 1957; Burnet 1970). In 
addition, the discovery that tumors formed in mice without an effective 
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immune system were more immunogenic than those formed in 
immunocompetent mice leaded to the cancer immunoediting hypothesis 
(Shankaran et al. 2001; Dunn et al. 2002; Schreiber et al. 2011). Such 
hypothesis discusses the different roles of immunity in tumor development: 
within the first phase (“elimination”), transformed cells are being detected 
and destroyed by cells of the innate and adaptive immunity, successfully 
suppressing tumor development. However, if some cancer cells are not 
destroyed, they enter the so-called “equilibrium phase”, in which tumor 
dormancy is induced by immunologic mechanisms preventing its outgrowth. 
This is also the phase where tumor editing occurs due to the constant 
immune selection pressure. This pressure leads to the rise of cancer cells 
that enter the escape phase where their outgrowth can no longer be blocked 
by the immune system. Those tumor cells can evade immune recognition or 
prevent immune destruction by the immune system and cause a clinically 
apparent tumor (Schreiber et al. 2011).  
1.1. Immune-mediated destruction of tumors 
Important steps to an efficient antitumor immune response are summarized 
in the cancer-immunity cycle (Chen and Mellman 2013). It starts with the 
release of cancer cell antigens from tumor cells that can be captured and 
processed by dendritic cells (DCs). In the next step, DCs present the 
captured antigens on MHC-I and -II molecules in the lymph nodes to T 
lymphocytes, leading to the priming and activation of those naive T cells 
against antigens derived from the tumor. The activated cytotoxic T 
lymphocytes (CTLs) traffic via blood vessels to the tumor and infiltrate it. In 
the tumor bed CTLs recognize cancer cells carrying their antigen and leads 
to the killing of the cancer cell and the release of more tumor-associated 
antigens (Chen and Mellman 2013) (Figure 1). Promoting an effective T cell 
response while overcoming the immune suppressive mechanism of the 
tumor is the key to successful destruction of cancer cells.  
4 




Figure 1. Generation of anti-tumor immunity (created with BioRender.com) 
 
1.2. Tumor-immune evasion strategies 
As previously indicated, tumors can evade destruction by the immune 
system through changes acquired at cell level or to the tumor 
microenvironment (TME). During their progression, tumors are able to 
acquire a large variety of these immune-evasion mechanisms in order to 
escape immune recognition. One example involves impaired antigen 
5 
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processing and presentation, including the loss or downregulation of the 
antigen presenting machinery (Khong and Restifo 2002; Leone et al. 2013; 
Seliger et al. 2000). Another form of alteration on tumor cell level is an 
increased resistance to immune-mediated apoptosis, for instance by the 
upregulation of anti-apoptotic molecules (Fernald and Kurokawa 2013). 
Furthermore, tumors are able to establish an immunosuppressive 
microenvironment by producing immunosuppressive cytokines such as the 
vascular endothelial growth factor (VEGF), transforming growth factor β 
(TGF-β) or interleukin-10 (IL-10) (Gabrilovich et al. 1996; Geissmann et al. 
1999; Wrzesinski et al. 2007; Steinbrink et al. 1999). Tumor cells can also 
express inhibitory molecules like PD-L1, which suppresses T cell function 
(Hamanishi et al. 2007). Another way tumor cells lead to impaired T cell 
function involves their metabolic activity: as rapidly dividing cells, tumor cells 
require high glucose uptake for fast energy production, even in the presence 
of oxygen (Hanahan and Weinberg 2011). As tumor cells can express higher 
level of nutrient transporters, T cells are exposed to a restricted level of 
glucose resulting in reduced T cell infiltration and antitumor activity (Singer 
et al. 2011; Chang et al. 2015). Overexpression of the glucose transporter 
GLUT1 in tumor cells is linked to a decreased level of CD8 T cells and a 
poorer survival rate in patients with ovarian cancer (Cho et al. 2013).  
Tumors are also able to recruit immunosuppressive immune cells into the 
tumor bed, including regulatory T cells (Tregs) or myeloid-derived suppressor 
cells (MDSCs). Tregs are able to suppress T cell function in several ways, for 
example by secreting TGF-β or IL-10 (Facciabene et al. 2012; Strauss et al. 
2007), or by expressing inhibitory molecules on their surface such as CTLA-
4 or PD-1 (Takahashi et al. 2000; Zhang et al. 2016). Tregs can also inhibit T 
cells by starving them of IL-2 an important cytokine for T cell function 
(Pandiyan et al. 2007). Another class of efficient inhibitors of effector T cells 
are MDSCs, a heterogeneous group of myeloid progenitors with multiple 
functions. MDSCs are not only able to attract Tregs (Huang et al. 2006), but 
6 
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they also produce immunosuppressive cytokines (Gabrilovich and Nagaraj 
2009) and induce angiogenesis (Yang et al. 2004). Like Tregs, MDSCs can 
sequester amino acids needed for T cell function (Srivastava et al. 2010).  
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2. Cancer immunotherapies 
During the last two decades, a novel kind of antitumor therapy has been 
added to the anticancer arsenal: cancer immunotherapies. The goal of these 
therapies is to overcome the acquired immune modulatory mechanisms of 
the tumor by stimulating and boosting the patient’s own immune system. 
There are different approaches to reinstall the immune system´s capability 
to induce an efficient, targeted antitumor immune response, and they include 
cancer vaccines, adoptive T cell transfer, immune checkpoint inhibitors and 
oncolytic virotherapy, which are detailed in the following sections. 
2.1. Cancer vaccines 
Antigen presentation is the first step in generating an antitumor immune 
response, so one attempt to induce tumor antigen specific T cells is the 
exogenous delivery of cancer antigens. Nevertheless, the effectiveness of 
cancer vaccines is limited, mostly due to suboptimal vaccine design and to 
the immunosuppressive tumor microenvironment. Improvements that need 
to be done involve the choice of antigen to immunize with, the delivery mode 
and possible combinational treatment to overcome tumors’ 
immunosuppressive mechanisms (Palucka and Banchereau 2013; Melief et 
al. 2015).  
2.2. Adoptive T cell therapy (ACT) and T cell engineering  
For adoptive T cell therapy (ACT), T cells are isolated from patient’s blood 
or tumor, modified or selected ex vivo, expanded and injected back into the 
patient, mostly after lymphodepletion to eliminate immunosuppressive cells 
like Tregs or MDSCs (Hinrichs and Rosenberg 2014).  
TILs (Tumor-infiltrating lymphocytes) therapies consist on isolating T cells 
from a tumor biopsy, select, and expand those able to recognize tumor cells. 
Studies using TILs in melanoma patients demonstrated an objective 
8 
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response rate between 50% and 70% with some complete responses (22%) 
(Rosenberg et al. 2011). Despite this encouraging result, this approach 
demonstrates some limitations, such as difficulty, time, and cost of selecting 
and expanding TILs. Furthermore, melanomas are the only type of cancer 
in which TIL therapy displayed clinical activity, probably due to high 
immunogenicity of melanomas compared to other tumor types (Hinrichs and 
Rosenberg 2014).  
Strategies to improve ACT and increase the application to other tumor types 
include the genetic engineering of the T cell receptor. One approach is the 
expression of transgenic T cell receptors (TCR) with higher antigen-
specificity and affinity on lymphocytes derived from a patient’s blood. 
However, limitations arise, as this technology is MHC-restricted and only of 
use in patients, whose tumor present the targeted antigen; tumors can 
downregulate MHC expression, limiting the clinical use of TCR-technology 
(Park et al. 2011).  
The second approach are the so-called chimeric-antigen receptor (CAR) T 
cells, which combine the antigen-recognition ability of antibodies with T cell 
activating functions. Firstly described by Eshhar et al., CARs consist of an 
antigen-binding single-chain fragment, which is variable, a transmembrane 
domain, and a signal transduction domain (Eshhar et al. 1993). That way, 
CAR-T cells do not depend on a cancer cells’ functioning antigen-expressing 
machinery, but target any potential cell surface antigen. One of the most 
investigated targets for CAR-T cells is CD19, which shows encouraging 
results in hematologic malignancies such as B cell leukemia and lymphoma 
(Turtle et al. 2016; Davila and Brentjens 2016; Strati and Neelapu 2019; 
Grupp et al. 2013). However, in solid tumors, the results of CAR-T cell 
therapies remain modest due to different obstacles. For example, the lack 
of suitable antigen targets, the complex tumor microenvironment, which 
makes it difficult for the T cells to enter the tumor bed, and the highly 
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immunosuppressive milieu existing within the tumor (Dai et al. 2016; 
Klebanoff et al. 2016; Yang 2015). Another major difficulty that needs to be 
addressed in CAR-T cells are the serious side effects, which include 
neurotoxicity and cytokine release syndrome (CRS) as a consequence of 
the uncontrolled release of proinflammatory cytokines (Morgan et al. 2010; 
Hartmann et al. 2017; Santomasso et al. 2019).  
2.3. Immune checkpoint inhibitors 
Non-specific immunotherapies boost cells from the innate and adaptive 
immune system without specifically targeting tumor antigens. These 
therapies include, for example, administration of interleukins, interferons, 
enzyme inhibitors, or immune checkpoint inhibitors (ICIs) (Berraondo et al. 
2019; Shirota et al. 2012; Baek et al. 2005; Vonderheide 2020).  
Immune checkpoints are inhibitory receptors expressed on the surface of 
immune cells that trigger immunosuppressive signaling pathways. The 
immune system has several of these immune checkpoints (e.g. Cytotoxic T 
Lymphocyte Antigen-4 (CTLA-4), Programmed Death-1 (PD-1), 
Lymphocyte Activation Gene-3 (LAG-3) and others) to regulate the 
amplitude and duration of induced responses in order to minimize collateral 
tissue damage during infection, and to generate and maintain self-tolerance. 
However, some tumors, take advantage of those mechanisms to suppress 
T cell activation and prevent destruction by the immune system resulting in 
hyporesponsiveness or T cell exhaustion (Pardoll 2012; Sharpe et al. 2007; 
Nirschl and Drake 2013). An approach to reinstall T cell function and 
enabling immune cells to destroy cancer cells is the use of antibodies that 
block the function of these “immune checkpoints” (Darvin et al. 2018). 
Ipilimumab, a monoclonal anti-CTLA-4 antibody, was the first immune 
checkpoint inhibitor approved by the FDA in 2011 for its use against 
metastatic melanoma, demonstrating prolonged overall survival (Hodi et al. 
2010; Yang 2015). CTLA-4 is a negative regulatory receptor on the surface 
10 
II LITERATURE REVIEW 
 
 
of T cells whose expression gets rapidly upregulated upon the activation of 
T cells (Krummel and Allison 1995). As a homologous to CD28, a key co-
stimulatory receptor in T cells, CTLA-4 competes with it for both, CD80 and 
CD86 ligands, but has higher affinity to them (Greene et al. 1996). Blocking 
of CTLA-4 enhances T cell activation as well as the depletion of Tregs in the 
TME (Peggs et al. 2009; Simpson et al. 2013) and therefore demonstrated 
encouraging clinical results. However, it also displayed immune-related 
toxicities in a subset of patients. The importance of CTLA-4 as an 
immunomodulator could be observed in CTLA-4 knockout mice showing a 
fatal autoimmune phenotype (Hodi et al. 2010; Waterhouse et al. 1995). 
Following the success of the CTLA-4 blockade, other immune checkpoints 
were investigated as potential targets for increased antitumor immune 
response. PD-1, which is expressed on activated T cells, B cells, antigen-
presenting cells (APCs) and NK-cells, inhibits T cell activity upon interaction 
with PD-L1 and PD-L2 (Ishida et al. 1992; Agata et al. 1996; Keir et al. 2008; 
Freeman et al. 2000; Latchman et al. 2001). The expression of PD-L1 has 
been detected in a variety of tumor cells to avoid destruction by the immune 
system (Jadus et al. 2012). These tumor cells revealed increased resistance 
to T cell-mediated lysis and Fas-induced apoptosis (Hirano et al. 2005; 
Azuma et al. 2008). Several immune checkpoint inhibitors targeting PD-1 
(e.g. nivolumab, pembrolizumab) and PD-L1 (e.g. atezolizumab) have 
reached the clinic and earned FDA approval (Topalian et al. 2014; Ansell et 
al. 2015; Brahmer et al. 2012; Mahoney et al. 2015; Powles et al. 2014). In 
addition, PD-1 and PD-L1 antagonists result in less severe side effects 
compared to CTLA-4 blockade, but severe pneumonitis has been observed 
in a small fraction of patients (Brahmer et al. 2010; Topalian et al. 2012).  
With multiple potential targets identified for immune checkpoint blockade, 
other immune checkpoint inhibitors are being investigated and hundreds of 
clinical trials are ongoing. Yet, the biggest hurdle of immune checkpoint 
11 
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therapy is that only a subset of patients is responsive. Different studies 
investigate potential biomarkers to predict which patients are most likely to 
respond to these therapies (Zappasodi et al. 2018; Rizvi et al. 2018; Snyder 
et al. 2014).  
2.4. Oncolytic virotherapy 
A rather new branch of cancer immunotherapy is the use of oncolytic viruses 
(OVs) as an intratumoral danger signal for the immune system. These 
oncolytic viruses were initially used as anticancer agents based on their 
restricted replication in malignant cells (Kirn et al. 2001; Guo et al. 2008). 
Cancer cell selectivity can be achieved by using viruses that are non-virulent 
in humans, but present replication in certain cancer cells due to their defects 
in interferon-responsiveness. These viruses include Newcastle disease 
virus (NDV) (Zamarin and Palese 2012; Pecora et al. 2002), vesicular 
stomatitis virus (VSV) (Lichty et al. 2004) and parvovirus (Angelova et al. 
2015). Another wild-type virus that is used as an oncolytic agent is reovirus, 
which merely causes mild symptoms in humans and present a natural 
restricted replication to cells with an activated Ras signaling pathway 
(Norman and Lee 2000; Hashiro et al. 1977; Duncan et al. 1978), such are 
most tumor cells (Norman et al. 2004; Maitra et al. 2012). In addition to these 
viruses presenting natural tropism for tumor cells, cancer-selective 
replication can also be achieved by genetic engineering. In the 1990s, 
genetic viral engineering started a new chapter in the oncolytic field, when a 
genetically engineered herpes simplex virus type I (HSV-1) with a mutated 
thymidine kinase gene showed successful application in human brain 
tumors (Martuza et al. 1991). Genetic modifications for this increased 
selectivity involve deletions of virulence genes redundant for viral replication 
in tumors (Guo et al. 2005; McCart et al. 2001), as many tumor cells display 
mutations in antiviral signaling pathways and therefore naturally favor viral 
replication (Hanahan and Weinberg 2011, 2000). Other alterations include 
use of tissue specific promoters for essential viral genes (Rojas et al. 2010).  
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Ever since a connection between viral infection and tumor regression was 
observed, people tried to treat cancer with different viruses (Hoster et al. 
1949; Taqi et al. 1981; Kelly and Russell 2007). Up to date, a wide range of 
different viruses are investigated for their use as OVs, with more than 90 
clinical trials reported during the last 20 years, mainly adenoviruses, HSV-1, 
reoviruses, and poxviruses (Macedo et al. 2020).  
Generally, oncolytic viruses promote antitumor responses through several 
distinct mechanisms. Because of viral replication within the tumor, tumor 
cells are lysed, which also leads to an amplification of the initial viral dose 
administrated. Importantly, such replication within the tumor environment 
can also result in indirect induction of antitumor immune responses (Lichty 
et al. 2014). Viral replication within tumor cells leads to tumor cell lysis and 
thereby to the release of tumor-associated antigens (TAAs), as well as 
different damage-associated molecular patterns (DAMPs) and pathogen-
associated molecular patterns (PAMPs), which can activate the innate and 
adaptive immune system (Rubartelli and Lotze 2007; Bartlett et al. 2013; 
Chiocca and Rabkin 2014) (Figure 2). This local intratumoral inflammation 
milieu can overcome the immunosuppression existing within the TME and 
promote antitumor immunity. The effect of oncolytic viruses can be 
enhanced by the expression of therapeutic transgenes, including different 
cytokines and anti-angiogenic proteins.  
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Figure 2. Antitumor activity of oncolytic viruses (created with BioRender.com) 
 
One of the oncolytic viruses most advanced in clinical development is a 
modified oncolytic herpes simplex virus type I called Talimogene 
laherparepvec (T-VEC). T-VEC displays a deletion in both the γ34.5 and the 
α47 genes, and an insertion of the human granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Hu et al. 2006; Liu et al. 2003). While γ34.5 
was deleted to achieve cancer cell-selective replication on one hand and to 
attenuate the virus neuropathogenicity on the other hand, α47 was deleted 
to enhance antigen presentation and therefore improve antitumor immune 
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responses (Chou and Roizman 1992; He et al. 1997; Goldsmith et al. 1998). 
To further increase the induction of antitumor immunity, the 
immunostimulatory cytokine GM-CSF was inserted into the viral genome 
(Hercus et al. 2009). After demonstrating its success in numerous clinical 
trials, T-VEC became the first oncolytic virus to be approved by the FDA in 
October 2015, followed by approval in Europe and Australia (Andtbacka et 
al. 2015; Ledford 2015; Senzer et al. 2009; Coffin 2016). 
Despite promising results achieved by oncolytic virotherapy, there are 
limitations faced by oncolytic viruses. The main issue is that oncolytic viruses 
can be recognized by the immune system as pathogens and therefore be 
cleared before they could induce a sufficient antitumor response. Especially 
when administrated intravenously, the antitumor effect is limited due to 
neutralizing antibodies, the complement system, and the sequestration in 
the liver or spleen (Gong et al. 2016; Russell et al. 2014). Additional 
obstacles for successful systemic administration are the dilution of the 
injected virus in the bloodstream and the limited permeability of tumor blood 
vessels, as well as other physical barriers faced within large tumors (Russell 
et al. 2012; Miller and Russell 2016). When administrated intratumorally, on 
the other hand, the virus may not be able to reach tumors in locations difficult 
or impossible to inject, leaving systemic administration as more effective, 
especially in case of metastatic cancer.  
To enhance the efficacy of oncolytic viruses, their combination with classical 
form of cancer treatments and immunotherapies like immune checkpoint 
inhibitors is under investigation (Rajani et al. 2016; Rojas et al. 2015; 
Puzanov et al. 2016).  
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3. Poxviruses as oncolytic agents 
3.1. Vaccinia virus – taxonomy and viral life cycle 
Vaccinia virus (VACV) is a member of the family Poxviridae, which can be 
divided into two subfamilies: Entomopoxvirinae specific for insects, and 
Chordopoxvirinae, which infect vertebrates. The Chordopoxvirinae consists 
of nine genera with Orthopoxvirus being the best-known genus because of 
its two famous members: variola virus and vaccinia virus. Variola virus is the 
causative agent of the human smallpox, and vaccinia virus is the vaccine 
used between 1958 and 1977 in the smallpox eradication campaign by the 
WHO (Fenner et al. 1988).  
Like all poxviruses, VACV is a large, oval to barrel-shaped, enveloped 
double-stranded DNA virus with 250 nm in diameter and 360 nm in length. 
An outer lipid membrane surrounds the biconcave core, containing an S-
shaped genome with linear dsDNA (130-300 kbp) and two lateral 
bodiesFehler! Verweisquelle konnte nicht gefunden werden.. Inverted 
terminal repeats (ITR) at the end of the genome form two single stranded 
hairpin loops (Baroudy et al. 1982). Genes located in the terminal region are 
often variable and mostly dedicated to host range or immune evasion 
functions, whereas genes in the central regions of the genome are highly 
conserved amongst poxviruses and essential for viral replication (Moss 
1996; Werden et al. 2008). Poxviruses exist in two infectious forms: 
intracellular mature virions (IMVs) and extracellular enveloped virions (EVs). 
IMVs are the majority of infectious progenies, which are released by cell lysis 
and responsible for host-to-host transmission. EVs possess an additional 
outer lipid membrane with associated proteins absent in IMVs and induce 
cell-to-cell as well as long-range spread (Payne 1978; Blasco and Moss 
1992). 
Poxvirus replication takes place in the cytoplasm (Figure 3) and, therefore, 
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poxviruses encode their own transcription machinery (Moss 1996). The 
multi-step process is regulated at a transcriptional level, with three classes 
of genes (early, intermediate, late), by transcription factors produced in each 
stage to promote gene expression onto the next level (Moss 1996; Baldick 
and Moss 1993; Broyles 2003; McFadden 2005; Moss 2013). Initially, the 
virion enters the host cell: in the case of IMVs, via plasma membrane fusion 
or actin-dependent micropinocytosis, and in the case of EVs, via disruption 
of the outer membrane and followed by fusion of the inner membrane with 
the cell’s plasma membrane (Law et al. 2006; Moss 2016). Cell entry of IMV 
is initiated by phosphatidylserine in the viral membrane (Mercer and 
Helenius 2008) and, for the entry of EVs, the F13 protein promotes the rapid 
entry into the cell (Bryk et al. 2018). The fusion of both infectious forms 
depends on the entry-fusion complex (EFC), which consists of twelve viral 
proteins of the IMV membrane (Moss 2012), leading to the release of the 
viral core, early transcription factors and DNA-dependent RNA-polymerase 
into the cytoplasm of the host cell (Moss and Earl 2001). Early gene 
expression starts immediately with those products leading to the uncoating 
and release of the viral genome and DNA replication (McFadden 2005). DNA 
replication takes place in the so-called viral factories, specific cytoplasmic 
sites surrounded by rough endoplasmic reticulum (Yuen and Moss 1987; 
Katsafanas and Moss 2007). Intermediate and late gene expression only 
occurs from replicated genome leading to the production of proteins 
necessary for DNA packaging, as well as virion morphogenesis and 
assembly; this includes structural proteins as well as early transcription 
factors to be packaged into newly assembled virions (Broyles 2003; Moss 
and Earl 2001). Most of the newly assembled IMVs are released from the 
cell approximately 72 hours after infection by cell lysis (Moss 2013). 
However, some of these IMVs are being wrapped with two additional 
membranes derived from the trans Golgi or endosomal membranes (Hiller 
and Weber 1985; Tooze et al. 1993; Schmelz et al. 1994). Subsequently, 
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microtubules transport them via microtubules to the cell surface and leave 
the cell by exocytosis (Ward and Moss 2001; Smith et al. 2002; Ward 2005; 
Blasco and Moss 1992). Some EVs are released from the cell surface and 
are responsible for wide-range transmission within the host (Payne 1980; 
Vanderplasschen et al. 1998) while the majority promotes efficient cell-to-
cell spread via an actin tail (Cudmore et al. 1995; Leite and Way 2015). 
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Figure 3. Poxvirus replication cycle (obtained from ViralZone; 
https://viralzone.expasy.org/4399, SIB Swiss Institute of Bioinformatics) 
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3.2. Immunomodulation by poxviruses 
The mammalian immune system is composed of two parts: the innate and 
the adaptive immunity. Upon viral infection, phagocytes, as part of the innate 
immune system, are activated by recognizing pathogen-associated 
molecular patterns (PAMPs) via their pattern recognition receptors (PRRs). 
This recognition leads to the expression of different cytokines and 
interferons (IFNs) to restrict viral replication, and to the induction of adaptive 
immunity. However, viruses have developed different immunomodulatory 
strategies to avoid detection and destruction by the immune system. 
Poxviruses, for example, dedicate almost half of their genomes to such 
immunomodulatory proteins, with most of them being expressed early during 
infection to counteract the innate immunity (Smith et al. 2013).  
3.2.1. Interferon response upon viral infection 
Upon viral infection, many different cytokines are produced, and type I 
Interferon (IFN-I) are in the first line of defense against viral infection. IFNs 
are secreted glycoproteins with potent antiviral effect (Honda et al. 2006). 
There are three classes of IFN (Pestka et al. 2004); type I IFN, first 
discovered over 60 years ago (Isaacs and Lindenmann 1957), includes IFN-
α, -β, -κ, -δ and -ω, which all bind to the ubiquitously expressed type I IFN 
receptor. IFN-α/-β are those type I IFNs induced directly upon viral infection 
and can be produced by all nucleated cells (Stark et al. 1998)). IFN-γ, as the 
single member of type II IFN, is only secreted by activated immune cells. 
Type III IFNs (IFN-λ) act, like IFN-α/-β, as a direct response to viral infection 
(Kotenko et al. 2003). The main function of IFNs, next to inducing apoptosis 
of infected cells, is to activate the expression of a set of proteins with antiviral 
activity, the so-called IFN-stimulated genes (ISGs). These include, protein 
kinase R (PKR), 2`-5`-oligoadenylate synthase (OAS), and the Mx protein 
(de Veer et al. 2001; Samuel 2001; Williams 1999; Silverman 1994; Haller 
and Kochs 2002), within others. Apart from inducing an antiviral state, IFNs 
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also have an impact on systemic immunity, especially regarding DC 
maturation and NK cell activation (Le Bon and Tough 2002; Stetson and 
Medzhitov 2006). 
Antiviral immune responses are initiated upon sensing of nucleic acids by 
PRRs in the cytosol or endosomes (Stetson and Medzhitov 2006; Pichlmair 
and Reis e Sousa 2007; Kawai and Akira 2010). Binding of PAMP to its PRR 
starts a signaling cascade, that includes the recruitment of specific adaptor 
molecules and the activation of different kinases, that ultimately leads to the 
activation of different transcription factors (IFN regulatory factor 3 (IRF3), 
IRF7, NF-κB and activator protein 1 (AP-1)). Those transcription factors 
translocate into the nucleus where they activate the promoter of genes 
encoding type I IFNs. Therefore, IFN-α/-β are secreted from the cell, binding 
to type I IFN receptors (IFNAR) in an auto- or paracrine manner, which 
triggers the Janus kinase (JAK) signal transducer and activator of 
transcription (STAT) pathway. The JAK/STAT signaling pathway culminates 
with the formation of a complex called IFN-stimulating gene factor 3 (ISGF-
3) that binds to IFN-stimulated response elements (ISREs) in the promoter 
region of IFN-stimulated genes (ISGs) leading to the expression of hundreds 
of antiviral proteins (Haller et al. 2006; Stark et al. 1998; Villarino et al. 2017).  
The importance of type I IFN as a defense mechanism against viral 
infections is demonstrated in different in vivo mouse models lacking IFN 
receptors or IFNs (Müller et al. 1994; Deonarain et al. 2000; van den Broek 
et al. 1995). Moreover, also humans with defects in the IFN signaling system 
are more susceptible to viral infections (Dupuis et al. 2003; Sancho-Shimizu 
et al. 2011). 
3.2.2. Blocking of IFN induction and IFN signaling pathways by VACV 
Poxviruses, including Vaccinia virus (VACV), inhibit IFN induction and block 
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IFN signaling pathways by multiple mechanisms at different levels (Smith et 
al. 2013). The first mechanism involves a specific arrangement of its genome 
for reducing production of PAMPs, such as dsRNA (Smith et al. 1998). In 
addition, VACV encodes for a variety of immunomodulatory genes to 
interfere with the IFN response. Such gene products can prevent that 
PAMPs or IFN reach their receptor, or block signaling pathways required for 
IFN induction. Because of the objective of this work, the focus here will be 
on VACV proteins that are known inhibitors of the IRF-3 signaling, as IRF-3 
is a critical participant in the regulation of type I IFN gene induction (Sato et 
al. 2000; Hiscott 2007). 
Under normal conditions, IRF-3 is constitutively expressed and resides in 
the cytoplasm in its inactive form. Upon sensing of viral infection by PRRs 
such as retinoic acid inducible gene I (RIG-I), melanoma differentiation 
antigen 5 (MDA5), DNA protein kinase (DNA-PK), or Toll like receptor 3 or 
4 (TLR3, TLR4), IRF-3 is phosphorylated by the kinases TANK-binding 
kinase 1 (TBK1) and IKKε, undergoes dimerization, and translocates into the 
nucleus. Here it binds to its binding sites within promoters of IRF-3-
dependent genes (mainly IFN-β) (Sharma et al. 2003; Fitzgerald et al. 2003; 
Lin et al. 1998; Yoneyama et al. 1998). To block this signaling, VACV 
codifies for different proteins with capacities to interfere the pathway at 
different levels (see also Figure 4):  
- Accelerated mRNA turnover is mediated by the highly conserved 
proteins D9 and D10, promoting the removal of the 5'-end 
m7GpppN cap (Parrish and Moss 2006, 2007; Parrish et al. 2007). 
This contributes to an increased host mRNA degradation and the 
prevention of viral mRNA accumulation and, consequently, the 
activation of dsRNA-responsive host innate immune sensing 
pathways, including PKR and OAS (Liu et al. 2014; Liu et al. 2015a; 
Burgess and Mohr 2015).  
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- E3 is a multifunctional protein, consisting of a C-terminal RNA-
binding domain and a N-terminal Z-DNA-binding domain. The 
sequestration of dsRNA via the C-terminal domain prevents 
activation of protein kinase R (PKR) and 2’-5’-oligoadenylate 
synthetase (OAS), the dsRNA-depending PRRs (Chang et al. 
1992; Brandt and Jacobs 2001; Kim et al. 2003). By preventing 
PKR activation, E3 interferes with three different signaling 
pathways: mitogen-activated protein kinase (MAPK), nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), and IRF3 
(Langland and Jacobs 2002; Myskiw et al. 2009). Furthermore, E3 
blocks sensing of RNA derived from AT-rich dsDNA after 
transcription by RNA polymerase III (Marq et al. 2009; Valentine 
and Smith 2010) and prevents virus-induced necroptosis in IFN-
treated cells (Koehler et al. 2017). The importance of the 
immunomodulatory function of E3 is apparent as its deletion blocks 
viral replication in most mammalian cell lines (Beattie et al. 1996).  
- Another viral protein preventing binding of PAMPs by PRRs is C10 
(also named C16 in the Western Reserve strain of VACV). By 
binding to the Ku subunits of DNA-PK, the C-terminal part of C10 
disrupts recognition of dsDNA by DNA-PK and thereby inhibits 
IRF3 activation (Ferguson et al. 2012; Peters et al. 2013).  
- The protein A46 is able to bind to different adaptor molecules 
downstream of Toll-like receptor signaling, including TIR-domain-
containing adaptor-inducing interferon-β (TRIF), TRIF-related 
adaptor molecule (TRAM), myeloid differentiation primary 
response gene 88 (Myd88) and Myd88 adaptor-like (MAL), which 
are associated with the cytoplasmic parts of TLRs (Bowie et al. 
2000; Stack et al. 2005). The blocking of TRIF and TRAM, both 
adaptor molecules required for the signaling of TLR3 and TLR4, 
leads to inhibition of the IRF3 signaling pathway (Lysakova-Devine 
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et al. 2010; Stack and Bowie 2012). In addition, the binding of these 
adaptor molecules blocks activation of MAPK and NF-κB as well.  
- The VACV protein C6 prevents activation of IRF3 by its interaction 
with the scaffold adaptor proteins of TBK1 and IKKε, the two 
kinases phosphorylating IRF3 (Unterholzner et al. 2011). In 
addition, C6 can inhibit the JAK/STAT signaling pathway in the 
nucleus by binding to STAT2 (Stuart et al. 2016). 
- Protein K7 blocks IRF-3 signaling by binding to DEAD-box RNA 
helicase 3 (DDX3), an adaptor of TBK1 and IKKε (Schröder et al. 
2008). In addition, K7 also binds to IL1-receptor-associated kinase 
2 (IRAK2) and TNF-receptor-associated factor 6 (TRAF6), both 
important ligands in the NF-κB pathway (Schröder et al. 2008; Oda 
et al. 2009). 
- Another protein interfering with IRF-3 signaling is N2, which inhibits 
the signaling pathway downstream of IRF-3 phosphorylation and 
nuclear translocation by yet unknown mechanism (Ferguson et al. 
2013). 
- Recently, a new inhibitor of the IRF-3 signaling pathway, encoded 
by the B2R gene, was identified by Eaglesham et al. and named 
poxvirus immune nuclease (poxin) (Eaglesham et al. 2019). Poxin 
neutralizes the effect of cGAMP, which is generated upon the 
sensing of dsDNA by the cyclic GMP-AMP synthase (cGAS) and 
acts as a second messenger and activator of the stimulator of 
interferon genes (STING). STING, once activated, is a scaffolder to 
TBK-1, inducing IRF-3 activation (Sun et al. 2013; Ablasser et al. 
2013; Liu et al. 2015b; Ishikawa et al. 2009).  
As can be observed, many immune evasion proteins encoded by VACV 
have multiple immunomodulatory functions on the IRF3 pathway (Smith et 
al. 2013). Furthermore, virus mutants lacking one or more of such genes are 
attenuated in vivo, demonstrating that, while some of those proteins may not 
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be essential, their functions are non-redundant (Benfield et al. 2013; Stack 
et al. 2005; Ferguson et al. 2013; Fahy et al. 2008).  
 
3.3. Poxviruses as viral vectors 
As mentioned before, due to the global vaccination program with VACV, 
smallpox was successfully eradicated in 1980, which makes it the first 
infectious disease that has been eradicated (Fenner et al. 1988). After that, 
the study of VACV for its use as expression and viral-vector based vaccine 
was continued (Mackett et al. 1982; Panicali and Paoletti 1982; Moss 1996). 
In terms of vaccine development, the use of VACV demonstrates multiple 
advantages, such as a potent inflammatory immune response that makes 
the additional use of adjuvants redundant (Akira et al. 2006; Ura et al. 2014). 
Figure 4. IRF3 signaling inhibition by VACV (obtained from Smith et al. 2013, 
modified with BioRender.com) 
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In addition, poxviruses, due to their own large genome, are able to 
incorporate large inserts of foreign DNA, even multiple genes at once (Smith 
and Moss 1983; Perkus et al. 1985). Furthermore, poxviruses have a good 
safety profile as the viral life cycle occurs completely in the cytoplasm of 
cells without any integration into the host genome (Roberts and Smith 2008). 
Because of side effects, especially in immunocompromised people, highly 
attenuated viruses, such as Modified Vaccinia virus Ankara (MVA), are of 
particular interest for vaccine development (Lane et al. 1969). MVA was 
generated after more than 500 passages of the chorioallantois VACV 
Ankara strain (CVA) in chicken embryo fibroblasts. Consequently, the virus 
lost large portions of its genome resulting in drastically impaired replication 
capacity, but in highly increased immunogenicity (Mayr and Munz 1964; 
Meyer et al. 1991; Antoine et al. 1998; Sutter and Moss 1992; Moss et al. 
1996; Drexler et al. 1998). Due to mutations and deletions in many 
immunomodulatory genes, MVA is able to efficiently induce type I IFN 
secretion after infection (Dai et al. 2014; Waibler et al. 2007). Nowadays, 
MVA is extensively studied as an expression vector and many recombinant 
MVAs have been developed as vaccine candidates against different 
infectious diseases or even therapeutic cancer vaccines (Volz and Sutter 
2017; Altenburg et al. 2014; Veit et al. 2018; Acres and Bonnefoy 2008).  
3.4. Oncolytic Vaccinia viruses 
In addition to its use as a viral vector for vaccine development, VACV is a 
promising candidate as an oncolytic agent. For the generation of oncolytic 
VACVs, different strains have been investigated, including Lister, 
Copenhagen, Wyeth, and specially, Western Reserve, which was derived 
from the Wyeth strain after several passages in mice (Zhang et al. 2007; 
Foloppe et al. 2008; Kim et al. 2006; Thorne et al. 2007; Kirn and Thorne 
2009).  
The most clinically-advanced oncolytic VACV is JX-594 (Pexa-Vec), which 
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is based on the Wyeth strain and it is modified by inactivating the thymidine 
kinase gene for achieving cancer cell selectivity, and it is armed with the 
transgene GM-CSF to enhance activation of antitumor immunity (Kim et al. 
2006). To date, Pexa-Vec has been tested in a variety of different tumors by 
intratumoral as well as intravenous administration, with highly promising 
results (Cripe et al. 2015; Park et al. 2015). It was able to reach distant 
metastasis when systemically administrated (Park et al. 2008) and, when 
administrated intralesional in melanoma-patients, regression of non-injected 
regional dermal metastases could be observed in 4 of 7 patients 
(Mastrangelo et al. 1999). More importantly, it was demonstrated that there 
is a correlation between administrated viral dose and prolonged survival 
(Heo et al. 2013). 
In order to achieve tumor cell selectivity in poxviruses, the deletion of viral 
genes such as the thymidine kinase gene (TK) is one of the most common 
strategies. By deleting TK, the virus is no longer able to produce high pools 
of nucleotides needed for viral replication (Buller et al. 1985). Yet, in most 
tumors, cellular TK expression is constitutively upregulated and allows 
VACV replication, whereas in normal cells TK is only expressed during the 
S phase in proliferating cells (Hengstschläger et al. 1994). The additional 
deletion of vaccinia growth factor (VGF), which induces proliferation in 
infected and surrounding non-infected cells by binding to the epidermal 
growth factor receptor (EGFR), demonstrated an increased tumor selectivity 
compared to the single deletion of TK (Buller et al. 1988; McCart et al. 2001; 
Thorne et al. 2007). Yet, replication-capacity is impaired in large panel of 
cancer cells when the two deletions are combined.  
As already mentioned, oncolytic viruses have different mechanisms of action 
to destroy cancer cells. In addition to the direct destruction of infected cancer 
cells due to viral replication, cell lysis leads to the release of different DAMPs 
and PAMPs as well as tumor and viral antigens (Rubartelli and Lotze 2007; 
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Bartlett et al. 2013; Chiocca and Rabkin 2014). This release of immune 
stimulatory-molecules can overcome the excessive immunosuppression 
that exists within the tumor and induce an in-situ vaccination effect for the 
released tumor antigens (Thorne 2011; Thorne et al. 2010). In order to 
improve this immune activation, the expression of transgenes to further 
enhance this antitumor effect has been explored. Different therapeutic 
transgenes have been tested, including cytokines, costimulatory molecules, 
or anti-vascular agents (Hermiston and Kuhn 2002; Kim et al. 2006; Kirn et 
al. 2007; Rojas et al. 2016). However, the main hinderance of excessive 
immune activation is the fine balance between activation of the immune 
system to destroy the tumor and premature clearance of the OV, which can 
result in reduction of the oncolytic efficacy.  
In addition, VACV displays another mechanism of action, thanks to their 
capacity to replicate in tumor-associated endothelial cells (Kirn et al. 2007). 
The destruction of these cells leads to a vascular collapse within the tumor, 
a disruption of the tumor blood flow, and, finally, to tumor necrosis (Breitbach 
et al. 2007). This viral-mediated destruction of vessels is restricted to the 
tumor due to a high pool of Vascular Endothelial cell Growth Factor (VEGF) 
within tumors, which activates endothelial cells and allows VACV replication 
(Arulanandam et al. 2015). 
All the poxvirus characteristics, combined with its different mechanisms of 
action against tumor cells, make VACV an attractive oncolytic vector. 
Advancements in the understanding of poxvirus biology, gene functions, and 
immunogenicity enables the improved logical design of genetically 







III OBJECTIVES  
Recently, oncolytic vaccinia viruses (VACV) have demonstrated their 
potential to provide for clinically effective cancer treatments. The reason for 
this clinical success is not only the direct destruction of infected cancer cells, 
but also the activation of immune responses directed against tumor 
antigens. For eliciting a robust antitumor immunity, a dominant Th1 cell 
differentiation of the response is preferred, and such polarization can be 
achieved by activating the Toll-like receptor 3 (TLR3)-interferon regulatory 3 
(IRF3) signaling pathway and, thus, activation of such pathway is 
suboptimal. However, current VACV used to date as oncolytic viruses still 
encode several immune evasion proteins involved in the inhibition of this 
signaling pathway. By inactivating genes of selected regulatory virus 
proteins, we aimed for a candidate virus with increased potency to activate 
cellular antitumor immunities but at the same time presents a fully 
maintained replicative capacity in cancer cells.  
For achieving this general objective, we stablished the following objectives: 
i. Generation of oncolytic VACV with deletions in 
immunomodulatory genes inhibiting IRF3 activation 
ii. Characterization of in vitro features and functional 
analysis of deleted VACV viruses  
iii. Evaluation of in vivo replication and anti-tumor immune 
response, and anti-tumor activity of deleted VACV viruses 
in syngeneic mouse tumor models 
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IV MATERIAL and METHODS 
1. Cells 
1.1. Cultivation of permanent cell lines 
All cell lines used in this work (MA104, HeLa, Renca, B16 and THP-1 cells) 
were obtained from the American Type Culture Collection (ATCC) and 
maintained in recommended culture media containing 5-10% heat-
inactivated fetal bovine serum (FBS) and 1% Penicillin/Streptomycin (P/S) 
at 37°C, 5% CO2. Table 1 and Table 2 detail the media used for culturing 
each cell line. Cell cultures were split 2 times per week when about 90% 
confluent, for which they were detached with Trypsin-EDTA.  
Table 1. Media/additives/cell culture 
Media/additives/cell culture Supplier 
Fetal bovine serum (FBS) SIGMA-ALDRICH, St. Louis, USA 
Penicillin-Streptomycin (P/S) SIGMA-ALDRICH, St. Louis, USA 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) 
SIGMA-ALDRICH, St. Louis, USA 
RPMI-1640 SIGMA-ALDRICH, St. Louis, USA 
RPMI 1640 Anprotec, Bruckberg, Deutschland 
L-Glutamine Lonza, Verviers, Belgium 
Sodium Pyruvat  SIGMA-ALDRICH, St. Louis, USA 
MEM Non-Essential-Amino Acid 
Solution 
SIGMA-ALDRICH, St. Louis, USA 
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Trypsin-EDTA SIGMA-ALDRICH, St. Louis, USA 
Antibiotic Antimycotic Solution SIGMA-ALDRICH, St. Louis, USA 
 
Table 2. Cell lines 
Cell lines Culture medium 
HeLa (human cervical carcinoma) 
MA104 (African green monkey 
kidney) 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) + 5% FBS + 1% 
P/S 
Renca (mouse renal 
adenocarcinoma) 
RPMI 1640 + 10% FBS + 1% P/S 
B16 (mouse melanoma) Dulbecco’s Modified Eagle’s 
Medium (DMEM) + 10% FBS + 1% 
P/S + 1% L-Glutamine + 1% 
Sodium Pyruvat + 1% MEM non-
essential Amino Acid Solution 
THP-1 (human leukemic 
monocyte) 
RPMI 1640 (anprotec) + 10% FBS 
+ 1% P/S 
1.2. Cell count 
Cells were trypsinized, diluted (1:2 or 1:4) and stained with Trypan blue 
(SIGMA-ALDRICH) solution for live/death staining before counting using a 
Neubauer Chamber. 
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2. Viruses 
2.1. Construction of recombinant viruses 
All recombinant replication-efficient viruses constructed or used in this 
research or constructed are based on the Vaccinia virus (VACV) strain 
Western Reserve (WR). To enhance selective replication in cancer cells, 
VACV WR/TK- was constructed by inactivation of the viral thymidine kinase 
gene (TK) though insertion of an expression cassette for the mCherry 
reporter gene under transcriptional control of the VACV late promoter P11. 
VACV WR/TK- was constructed prior to this study by Dr. Juan J Rojas and 
served as backbone for deleting VACV genes in this study.  
The C6L, C10L and N2L genes were inactivated by homologous 
recombination replacing the original gene sequence with a synthetic 
construct containing two 350 base pair DNA sequences upstream and 
downstream of the genomic site targeted for insertion. In addition, the start 
codon in the synthetic gene sequence was mutated. For generation of 
recombinant oncolytic VACVs, 1x106 MA104 cells were seeded in 6-well 
plates and infected with the parental backbone virus at a MOI of 1 and, 3 
hours later, cells were transfected using Lipofectamine 2000 (Fisher 
Scientific) with recombinant pUC18-GFP plasmid containing the respective 
synthetic gene construct. Such plasmid contains a green fluorescent protein 
(GFP) for facilitating isolation of recombinant viruses. At 48 hours after 
infection, cell cultures were harvested, and the GFP marker was used for 
isolation of clones (Figure 5: transitory recombinant viruses express now 
red (mCherry) and green (GFP) fluorescence). Once recombinant clones of 
this transitory form were isolated, viruses incorporating a second 
homologous recombination between the synthetic gene and the original 
gene are selected. In such recombination, we have a 50% of chances of 
successfully replace the original gene with our deleted version (see Figure 
5: now recombinant viruses express only mCherry). PCR analysis using 
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oligonucleotide primers flanking deletion sites are necessary to confirm the 
correct modification in the isolated clones. PCR analyses were performed 
with oligonucleotide primers flanking the deletion sites and sequencing were 
further necessary to confirm the correct genetic modification of plaques with 
red fluorescence. Figure 5 depicts schematic diagram of the construction of 
the deletion viruses, presented on the example of the deletion of the C6L 
gene from WR/TK-. 
 
Figure 5. Scheme of the construction of the deletion viruses 
 
The non-replicative strain MVA was generated prior to this study by Prof. Dr. 
Gerd Sutter and Astrid Freudenstein and served as positive control for the 
Western Blot analysis and mRNA-expression analysis. This recombinant 
MVA contains a mCherry-expression cassette under transcriptional control 
of the P11 promoter inserted into deletion III. It was based on the MVA clonal 
isolate F6 (Sutter 1990 LMU thesis). 
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2.2. Virus amplification, purification and titration 
All deletion viruses were propagated in HeLa cells for purification. 60 flasks 
of 150 cm2 containing HeLa cells monolayer were infected at a MOI of 1 and 
incubated for 2-3 days at 37° C until extensive cytopathic effects could be 
observed. Then, cells were mechanically de-attached, transferred into 50 ml 
falcons and centrifuged at 1250 rpm for 5 minutes at 4°C. The supernatant 
was discarded and cells were resuspended with 45 ml 10mM Tris-HCl pH 9, 
before being frozen to -80°C. 
After three freeze-thaw cycles, cell-suspensions were homogenized using a 
douncer homogenizer and submitted to three cycles of sonication. Samples 
were centrifuged at 1250 rpm for 5 minutes at 4°C and the virus-containing 
supernatant was carefully collected. In 6 ultracentrifuge tubes, 18 ml of a 
36% sucrose solution (SIGMA-ALDRICH, in 10 mM Tris-HCl pH 9) were 
carefully overlaid with 7,5 ml of virus-sample, before they were 
ultracentrifuged at 15 000 rpm for 1 hour and 20 minutes at 4°C. Afterwards, 
the supernatant was discarded and the virus pellets resuspended in 20 ml 
of a 10 mM Tris-HCl pH 9. For digestion of contaminating DNA, 3µl of 
Benzonase (VWR) were added to the samples and incubated 2 hours at 
room temperature. Consecutively, the virus suspension was filtered 
(Spectrum Labs™ MICROKROS HOLLOW FIBER FILTER MODULE 1XFL 
PS 0.05, Fisher Scientific) to discard endotoxins, concentrating the volume 
to 2ml. After readjusting the volume to 15 ml with fresh 10 mM Tris-HCl pH 
9, the sample was submitted to another round of ultracentrifugation as 
described above, dividing the volume within 2 ultracentrifuge tubes. Again, 
the supernatant was discarded and the remaining virus pellets were finally 
resuspended in 1.2 ml 10 mM Tris-HCl pH 9, aliquoted and stored at -80°C. 
Every time before usage, virus stocks were thawed on ice and submitted to 
three cycles of sonication. 
To determine an accurate viral titer, viruses were tittered three times in 
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parallel in confluent 6-well plates of MA104 cells. In duplicates, the wells 
were infected with prepared virus dilutions (10-6, 10-7, 10-8) and overlaid with 
a 1:1 mixture of 3% CMC (Carboxymethylcellulose sodium salt, low 
viscosity, SIGMA-ALDRICH) and cell culture media, cultured for three days 
at 37°C, and dyed with crystal violet. Viral titer was calculated in plaque 
forming units per milliliter (PFU/ml) by counting the plaques formed in each 
dilution.  
3. Virus growth assay and plaque size  
2x105 cells were seeded in 24-well plates and infected with a multiplicity of 
infection (MOI) of 5 or 0.05. One hour after infection, cells were washed with 
PBS and new pre-warmed media was added. At different time points (0, 4, 
12, 24, 48 and 72 hours after infection), samples were harvested and frozen 
at     -80°C. Viral titer was determined by plaque assay after three freeze-
thaw cycles.  
To assess the size of the plaques formed by different viruses, MA104 cells 
were infected at a MOI of 0.05 and, 72 hours post infection, the diameter of 
plaques was measured after crystal violet dying (SIGMA-ALDRICH). 
4. In vitro cytotoxicity assay 
Cytotoxicity assays were performed by seeding 5x104 cells in 96-well plates. 
Cells were infected with 1/5-serial dilution starting at a MOI of 150 (ranging 
from 150 to 0.0001) and incubated at 37°C for 72 hours. After three days, 
cells were checked for remaining metabolic activity using a non-radioactive 
cell proliferation assay (CellTiter96® Aqueous Non-radioactive cell 
proliferation assay, Promega) following the manufacturer’s instructions. 
Absorbance was measured at a wavelength of 450 nm (Sunrise™, Tecan 
Trading AG) and metabolic activity was quantified. 
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5. Polymerase chain reaction (PCR)  
To obtain viral DNA samples for PCR, one well of a confluent 6-well plate of 
HeLa cells was infected at an MOI of 1 and incubated for 3 days. 200µl of 
infected culture were used for DNA extraction using a QIAmp DNA Mini Kit 
(Qiagen). DNA concentration was determined using the NanoDrop® 
(PEQLAB Biotechnology GmbH). 
Polymerase chain reaction (PCR) was performed with 50-150 ng of DNA 
(10µl) per sample and 40µl of a PCR Master Mix, consisting of 1 µl of 10 µM 
forward Primer, 1 µl of 10 µM reverse Primer, 25 µl of OneTaq® Mix (New 
England Biolabs) and 13 µl of distilled water, using a peqSTAR 2x 
thermocycler (PEQLAB Biotechnology GmbH). Primers used for the 
different PCRs performed in this work are summarized in Table 3, and 
conditions of the different PCRs are summarized in Table 4. 
Table 3. Specific oligonucleotide primers 
Primer Sequence Size 
C10-F 5’ – AGT AAA ATC TAG TTA CCT TG – 
3’ 
1311 bp 
(∆C10 = 670 
bp) C10-R 5’ – TAT AAT TCT ATT ACA CCG GC – 
3’ 
C6-F 5’ – ACT GTA AAT TTC TCA ACG CG – 
3’ 
1083 bp 
(∆C6 = 682 bp) 
C6-R 5’ – ATC TTA AAC ATG GTA TTA CG – 
3’ 
N2-F 5’ – ATG TAC ATA CAT CGC CGT CA – 
3’ 
1126 bp 
(∆N2 = 693 bp) 
N2-R 5’ – GTA GAC TTT GTA GTT AAC GG – 
3’ 
36 





5’ – TGC TCT CCT GTT GTG CTT CTC 




5’ – CAG TGA CTG TAC TCC TTG GCC 























5’ – ATG GAA AGA TCA ACC TCA CCT 




5’ – TAG ATT CAC TAC CAG TCC CAG 




5’ – GAC AAC TCA CTC AAG ATT GTC 





5’ – GTA GCC GTA TTC ATT GTC ATA 
CC – 3’ 
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Table 4. Thermocycling conditions 
C10-/C6-/N2-PCR 
Step Temperature Time 
Initial denaturation 94°C 30 seconds 





1 minute 20 seconds 
Final extension 68°C 5 minutes 
Store 4°C forever 
IFN-β-mRNA-PCR 
Step Temperature Time 
Initial denaturation 95°C 3 minutes 






Final extension 72°C 5 minutes 
Store 4°C forever 
GAPDH-/E3L-mRNA-PCR 
Step Temperature Time 
Initial denaturation 95°C 3 minutes 






Final extension 72°C 5 minutes 
Store 4°C forever 
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The size of the PCR products was analyzed by gel electrophoresis using 1% 
agarose gels with added GelRed (VWR) and 1X TAE buffer (Fisher 
Scientific) as running buffer. A 1kb DNA ladder (New England Biolabs) was 
used as a molecular weight marker. The nucleic acid bands were visualized 
with a ChemiDoc™MP Imaging system (Bio-Rad). 
6. Protein analysis 
Indicated cells were seeded in 24-well plates and infected with a MOI of 10. 
5 hours after infection, cells were harvested using Trypsin-EDTA, 
resuspended with suitable medium and centrifuged at 1250 rpm for 10 
minutes at room temperature. Cells were washed with PBS and lysed using 
RIPA buffer (Abcam) supplemented with 1% Protease-Phosphatase-
Inhibitor Cocktail (Half™ Protease & Phosphatase Inhibitor Cocktail, Fisher 
Scientific). After an incubation time of 30 minutes at 4°C, supernatant and 
cell debris was separated by centrifugation for 10-15 minutes at 4°C and 13 
000 rpm. The supernatant was collected and frozen at -20°C.  
For protein quantification, a BCA assay kit (Pierce™ BCA Protein Assay Kit, 
Fisher Scientific) was used according to the manufacturer’s instruction 
before absorbance was measured at 560 nm and protein amounts 
calculated.  
To load equal amount of proteins into the gel, samples were diluted with lysis 
buffer and 4X loading buffer (9 parts Laemli buffer (Bio-Rad), 1 part β-
Mercaptoethanol (Carl-Roth GmbH). The samples were then boiled at 95°C 
for 5 minutes before being loaded onto a 10% SDS-gel (Mini-PROTEAN® 
TGX™ Gels, Bio-Rad). The Precision Plus Protein™ Dual Color Standard 
(Bio-Rad) was used as a molecular weight marker. The protein 
electrophoresis was performed in 1X Tris/Glycin/SDS running buffer (Bio-
Rad) at 80-130 V for about 90 minutes (Mupid®-One, Mupid). Proteins were 
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then transferred to a nitrocellulose blotting membrane (Amersham™ 
Protran™ Premium 0.2µm NC, GE Healthcare Life Science) with 1x transfer 
buffer using the Trans Blot Turbo system (Bio-Rad). The membrane was 
blocked with 1X Tris buffered saline with 0.1% Tween®20 (Promega) 
(TBS/Tween) and 5% BSA (Bovine serum albumin, SIGMA-ALDRICH) for 1 
hour at 4°C. Afterwards, the blot was incubated overnight at 4°C with a rabbit 
anti-P-IRF3 primary antibody diluted 1:1000 in TBS/Tween 1% BSA. The 
following day, the blot was washed 4 times 10 minutes with TBS/Tween 
before incubation with a secondary anti-rabbit IgG HRP-linked antibody, 
1:5000 diluted in TBS/Tween-1% BSA, for 1 hour at room temperature. 
Again, the blot was washed 4 times for 10 minutes with TBS/Tween before 
ECL Plus kit (Pierce™ ECL Plus Western Blotting Substrate, Fisher 
Scientific) was used following manufacturer’s instructions and bands were 
analyzed using ChemiDoc™ MP Imaging System (Bio Rad). See Table 5 
for used antibodies.  
Table 5. Antibodies used for Western Blot analysis 
Antibody Dilution Company 
P-IRF-3 (S396) rabbit 
mAB 








1:5000 Cell Signaling, 
Danvers, USA 
For the Glycerinaldehyd-3-phosphat-Dehydrogenase (GAPDH) loading 
control, the blot was stripped using Restore™ Western Blot Stripping Buffer 
(Fisher Scientific) for 45 minutes at 37°C and washed 3 times, 10 minutes 
with TBS/Tween. Again, the blot was blocked with TBS/Tween-5% BSA for 
1 hour at 4°C before overnight incubation with rabbit anti-GAPDH antibody, 
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1:100 diluted in TBS/T-5% BSA. After further washing, incubation with the 
secondary anti-rabbit IgG HRP-linked Antibody (1:5000) in TBS/Tween-1% 
BSA was performed and ECL Plus kit was used as described above. 
7. mRNA expression analysis 
1x106 cells were seeded in 24-well plates and infected at a MOI of 5. At 6 
hours post-infection, cells were harvested using Trypsin-EDTA and 
centrifuged at 1300 rpm for 5 minutes at 4°C. Total RNA was purified, using 
an RNeasy-Plus Kit (Qiagen) following manufacturer’s instructions. cDNA 
was synthesized from the template RNA using a Omniscript RT Kit (Qiagen), 
following the manufacturer’s instructions and PCR was performed using 
specific primers for the mRNA of interest (see Table 3).  
8. In vivo experiments 
8.1. Mouse models 
All animal experiments were handled in compliance with the German 
regulations for animal experimentation (Animal Welfare Act, approved by the 
Government of Upper Bavaria, Munich, Germany). 6-8 weeks old female 
BALB/c (Renca tumor model) or C57Bl/6 (B16 tumor model) mice were 
purchased from Charles River Laboratories and housed in an isolated (ISO) 
cage unit with free access to food and water.  
8.2. Tumor implantation and virus administration 
Tumor cells for implantation were maintained in vitro at standard conditions. 
At the day of implantation, cells were trypsinized, centrifuged at room 
temperature for 7 minutes at 1200 rpm, washed with PBS, counted, and 
resuspended in an appropriate volume of PBS for implanting 5x105 cells in 
41 
IV MATERIAL and METHODS 
 
100µl. The tumor cells were subcutaneously injected into the flank of mice. 
Prior to injection, mice were anesthetized using 3% isoflurane (cp-pharma) 
and the fur on the flank was clipped for easier observation of the tumor 
growth.  
When the tumors reached 50-100 mm3 in size, mice were randomized and 
viruses were administrated intratumorally at a dose of 1x107 PFU in a 
volume of 10 µl.  
Tumor volume was defined by the following equation: 
𝑉(𝑚𝑚3) =  
𝜋
6
 𝑥 𝐿 𝑥 𝑊2 
W stands for width and L for the length of the tumor. These parameters were 
determined by caliper measurements. 
After virus injection, weight of mice was checked daily and the mice were 
scored daily following the scoresheet described in Table 6. 
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Table 6. Scoresheet for in vivo mouse experiments 
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8.3. Study of viral replication in vivo 
Tumors were established as described above. After randomization of mice 
(n = 4-6), they received at day 0 a single intratumoral dose of 1x107 PFU. 
Mice were sacrificed 4 days after virus administration and tumors were 
harvested, washed with PBS, and fluorescence signal emitted from virally 
expressed mCherry acquired using a Geldoc imaging system (Bio-Rad) and 
quantified using ImageJ. 
For determining the viral titer within the tumors, mice were treated as 
described above and sacrificed at day 4 after viral administration. Tumors 
were harvested, weighted, and 300µl of cold PBS supplemented with 20% 
Antibiotic Antimycotic Solution (SIGMA-ALDRICH) was added. Tumors were 
homogenized using metal beads and a tissue homogenizer (TissueLyser II, 
Quiagen) for 1 minute, before centrifugation at 2000 rpm for 2 minutes at 
4°C. After centrifugation, the supernatant was collected and virus titer was 
determined by plaque assay as previously described, adding 1% Antibiotic 
Antimycotic Solution for avoiding contaminations. 
8.4. In vivo antitumor activity 
Tumors were established as described above. Mice were treated twice (day 
0 and day 4) with an intratumoral dose of 1x107 PFU of indicated virus. Mice 
were monitored daily, tumors were measured 3 times per week using a 
caliper, and tumor volume was calculated as described before. Mice were 
euthanized by cervical dislocation when tumors reached termination criteria. 
8.5. IFN-γ ELISpot 
Tumors were established as described above and mice were treated twice 
(day 0 and day 4) with an intratumoral dose of 1x107 PFU of indicated virus. 
5 days after the second virus injection, mice were sacrificed and the spleens 
harvested. After passing through a 70 µm strainer (Falcon®, A Corning 
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Brand) and incubating with Red Blood Cell Lysis Buffer (SIGMA-ALDRICH), 
splenocytes were washed with RPMI-1640 supplemented with 10% FBS. 
2x105 cells were cultured for 48 hours at 37°C and 5% CO2 in anti-IFN-γ 
(MABTECH) pre-coated 96-well plates together with 2µg/ml of peptides. The 
synthetic peptides used for restimulation were B8R20-27, gp100 and B16-
M30mut (see Table 7, peptides were dissolved in PBS to a concentration of 
2mg/ml). Cells treated with phorbol myristate acetat (PMA) (SIGMA-
ALDRICH) and ionomycin (SIGMA-ALDRICH) were used as a positive 
control. The ELISpot kit was used following the manufacturer’s instructions. 
An automated ELISPOT reader software (A.EL.VIS Eli.Scan, A.EL.VIS 
ELISPOT Analysis Software) was used for counting and analyzing.  
Table 7. Synthetic peptides used for IFN-γ-ELISpot analysis 




9. Statistical analysis 
Standard student’s t test (two-tailed) was used for analyzing results in Figure 
9 and 10. A one-way ANOVA and Tukey’s Multiple Comparison test was 
used for analyzing Figure 13 and 15. In Figure 14, a Two-way ANOVA and 
Bonferroni posttest was chosen for analyzing tumor growth curves and a log 






1. Generation of oncolytic VACV with deletions in key 
genes blocking activation of IRF3 pathway 
To improve cellular immune responses, we modified the candidate oncolytic 
VACV WR/TK- (Rojas et al. 2016) (Western Reserve strain of VACV with a 
deleted thymidine kinase gene) by inactivating a set of viral genes involved 
in interfering with the IRF3 signaling pathway. Three genes were selected 
and sequentially deleted (Figure 6): C6L, N2L and C10L. C6 interacts with 
the scaffold proteins NAP1, TANK, and SINTBAD (Unterholzner et al. 2011; 
Smith 2018); N2 inhibits nuclear IRF3 (Ferguson et al. 2013); and C10 
(named C16 in the WR strain) inhibits DNA-PK-mediated DNA sensing 
(Peters et al. 2013; Scutts et al. 2018). Figure 6 schematically depicts 
deletions present in the genomes of the viruses tested in this study (WR/TK-
/∆, WR/TK-/2∆, and WR/TK-/3∆). 
Schematic diagram of VACV genomes indicat ing the posit ions of the 
viral genes targeted by sequential delet ion. For the prospect of 
monitoring vi ral repl icat ion, an expression cassette encoding the red 
f luorescent marker protein mCherry was inserted into the Thymidine 
Kinase (J2R) site of the vi rus genomes.  
Figure 6. Generation of oncolytic VACV with accumulated deletions in key 





Correct genetic modifications of the viral genomes were confirmed by PCR 
analysis with oligonucleotide primers flanking the deletion sites (Figure 7) 
and by sequencing. 
Expected size of the PCR products are: C10L = 1311 bp, ∆C10L = 670 





Figure 7. PCR-analysis to confirm deletions in target genes. 
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2. Deletion of genes blocking the IRF3 pathway mainly 
do not interfere with oncolytic VACV in vitro features 
2.1. Growth analysis of oncolytic deletion VACV 
Maintaining an efficient replication of the vector virus in cancer cells is 
important for achieving an effective oncolytic activity. Therefore, we 
evaluated whether the deletions or the combination of deletions in the viral 
genomes have an influence on VACV replication in cancer cells. For one-
step-growth or multiple-step-growth analysis, we infected HeLa cells with 
candidate viruses at multiplicities of infection (MOI) of 5 or 0.05 and, at 
indicated time points, cultures were harvested to determine viral titers by 
plaque assay. Both under one-step-growth (Figure 8. Mainly unimpaired 
replication of mutant VACV witch single and accumulating deletions in genes inhibiting 
the IRF3 signaling pathway.A+B) or multiple-step-growth conditions (Figure 
8C), all candidate viruses replicated to titers similar to those obtained with 
the parental WR/TK- virus. All VACV with single, and double, deletion in 
candidate genes were tested under one-step-growth conditions in order to 
discard effect of single mutations in candidate viruses with multiple genes 
deleted. All candidate viruses replicated to titers similar to those obtained 
with the parental WR/TK- virus. The size of virus plaques formed in cell 
monolayers after infection can serve as an indicator of the viral capacity to 
destroy target cells upon propagation. In MA104 cells, the plaques lesions 
formed after infection with the candidate viruses were not significantly 
different in size compared to those formed after infection with WR/TK-, 
although we observed a tendency for plaque size reduction with 


















Product ive mult ipl icat ion of delet ion mutant viruses. HeLa cel ls were 
infected with a mult ipl ic i ty of infect ion (MOI) of 5 (A+B) or 0.05 (C) and,  
at indicated t ime points, samples were col lected and vi ral t i ters were 
determined by plaque-assay. Virus yield was evaluated in 
quadrupl icate. (D) Plaque size analysis in MA104 cel ls.  MA104 cel ls  
monolayers were infected at a MOI of 0.05 and, 72hours post infect ion, 
stained with crystal violet solut ion before the diamete r of plaques was 
measured. The diameter size (µm) of 25 representat ive plaques per 
virus and mean ±SD are depicted.  
 
 
Figure 8. Mainly unimpaired replication of mutant VACV witch single and 






2.2. Evaluation of the cytotoxic capacity of oncolytic deletion 
VACV 
Then, we assessed whether the candidate oncolytic VACV conserve an 
unimpaired capacity to kill cancer cells. We infected both human (HeLa) and 
mouse cancer cell lines (Renca and B16) at different MOI (ranging from 
0.0001 to 200) and, 72 hours after infection, the remaining metabolic activity 
of cells was determined (Figure 9A). The capacity to kill cancer cells was 
not affected by the accumulation of gene deletions and resulted in very 
similar patterns of cell death for infections with WR/TK-/∆, WR/TK-/2∆ and 
WR/TK-/3∆ compared to the parental virus WR/TK-. Again, all the possible 
combinations of single and double deleted viruses were tested in order to 




Figure 9. Viruses with deletions in genes involved in interfering with the IRF3 
signaling pathway maintains capacity to kill cancer cells. 
Comparat ive cytotoxicity in human and mouse tumor cel l  l ines. Cells 
were infected with indicated viruses at doses ranging from 200 to 








3. Deletion of viral genes interfering with the IRF3 
signaling pathway leads to phosphorylation of IRF3 
and expression of IFN-β-mRNA 
To evaluate whether infection with candidate oncolytic VACV (WR/TK-/∆, 
WR/TK-/2∆, and WR/TK-/3∆) leads to activation of the IRF3 pathway, we 
tested the phosphorylation status of IRF3 by Western Blot. As a positive 
control for the activation of the IRF3 pathway we used infections with the 
replication-deficient Modified Vaccinia Virus Ankara (MVA), which is a 
natural VACV mutant with many inactivated viral genes and it is known to 
efficiently activate IRF3 (Lehmann et al. 2016). In HeLa cells, levels of 
phosphorylated IRF3 were not increased by the presence of deletions 
compared to the parental virus WR/TK- (Figure 10A). However, both in 
THP-1 cells (Figure 10. Activation of the IRF3 pathway by candidate oncolytic 
VACV due to accumulation of genomic deletions.B) and in the mouse tumor cell 
line B16 (Figure 10C), we detected increasing amounts of phosphorylated 
IRF3 upon infection with viruses accumulating inactivations in genes 
interfering with the IRF3 pathway. Effects of single gene deletions were 
discarded by Western Blot analysis of extracts from THP1 cells infected with 
mutant viruses including all possible combinations of C10L, N2L, and C6L 




Delet ion of viral genes interfering in the IRF3 pathway leads to IRF3 
phosphorylat ion. HeLa (A+E), THP-1 (B+D), and B16 (C) cel ls were 
infected with the indicated viruses at a MOI of  10 and,  5 hours after  
infect ion, cel ls were lysed and Western Blot analysis was performed 
using a monoclonal ant ibody against phospho -IRF3. The non-
repl icat ing VACV MVA (Modif ied Vaccinia vi rus Ankara) served as a 




Figure 10. Activation of the IRF3 pathway by candidate oncolytic VACV due to 





IRF3 activation was confirmed by RT-PCR of Interferon-β in all cell lines 
tested. We detected increased levels of Interferon-β mRNA upon infection 
with the WR/TK-/3Δ virus (Figure 11 
). Of note, this finding includes infections of HeLa cells, where increased 
levels of phosphorylated IRF3 protein could not be detected by immunoblot 
analysis. 
HeLa (A), THP-1 (B), and B16 (C) cells were infected at a MOI of 5. At 6 hours after 
infection, total RNA was obtained and indicated the mRNAs of indicated genes were 
amplified by RT-PCR. The detection of VACV E3L mRNA was used as an infection 
control and GAPDH mRNA as a loading control. 




4. In vivo evaluation of oncolytic VACV with deletions 
in the TLR3-IRF3 pathway 
4.1. Replication of deletion mutant viruses is not impaired in 
mouse tumor models 
To ensure that virus replication remains unimpaired in vivo, we injected mice 
bearing Renca tumors (mouse renal adenocarcinoma) intratumorally with 
the candidate deletion-mutant viruses and 4 days after virus injection tumors 
were harvested and viral growth was evaluated. Taking advantage of 
mCherry co-expression, fluorescence emitting from tumor tissues was 
quantified (Figure 12A+B). In addition, we titrated the virus loads within 
tumors (Figure 12C). Both methodological approaches illustrated that 
deletion mutant viruses and the parental virus WR/TK- replicated to very 
similar levels in tumor tissues. This indicates that deletion of up to three 
genes interfering with the IRF3 pathway does not hinder effective VACV 






5 x 105  Renca cel ls were subcutaneously implanted on the f lank of 6 -8 
week old Balb/C mice (n = 4 to 5).  At day 0, a dose of 1x107 PFU was 
intratumoral ly injected and,  4 days later,  mice were sacri f iced and 
tumors were harvested. (A) Images of representat ive tumo rs showing 
mCherry-specif ic f luorescence. (B) Tumor f luorescence quanti f ied 
using a MacroImaging system. Fluorescence of individual tumors and 
group means +SD are shown. (C) Viral t i ters determined by plaque 
assay after tumor homogenizat ion. Titers obtaine d from each 
independent tumor and means +SD are depicted.  




4.2. Improved antitumor activity of oncolytic candidate VACV 
As a next step, we evaluated the antitumor efficacy of the deletion mutant 
VACV in vivo using intratumoral virus delivery in two syngeneic mouse tumor 
models: BALB/C mice bearing Renca tumors and C57/BL6 mice bearing 
B16 tumors. In the Renca model, the injection of WR/TK-/2∆ or WR/TK-/3∆ 
viruses resulted in a strong significant reduction of tumor growth in 
comparison to the therapeutic effect observed with the parental WR/TK- 
(Figure 13A). Additionally, we also observed an increased survival time of 
mice injected with double and triple deletion mutant VACV (Figure 13B). 
When tested in the mouse melanoma tumor model B16, the WR/TK-/3∆ 
virus also induced a significant reduction in tumor growth (Figure 13C), but 


























Figure 13. Increased in vivo antitumor activity of candidate oncolytic VACV with 
combination of gene deletions rescuing IRF3 activation. 
5x105  tumor cel ls were subcutaneously implanted at day -9 on the f lank 
of 6-8 week old BalbC mice (Renca tumors, a -b) or C57Bl/6 (B16 
tumors, c-d),  and vi ruses were intratumoral ly administered at days 0 
and 4 at a dose of 1x10 7  pfu/ inject ion. PBS injected mice served as 
controls. For monitoring tumor growth, the tumors were measured 2 -3 
t imes per week unt i l  terminat ion cri teria were reached. Tumor volume 
(A, C) and overal l  survival (B, D) are plotted for 7 -9 mice per group 
+SEM; (E-F) Renca (E) and B16 (F) tumor  growth curves of individual  
animals treated with candidate oncolyt ic VACV*, p<0.05; **,  p<0.01,  





4.3. Induction of tumor-specific cellular immune response by 
deleted VACV viruses 
Our hypothesis was that the increased antitumor activity of deleted VACV is 
mediated by a more robust cellular antitumor immunity. Thus, we evaluated 
the tumor epitope-specific T cell responses established following virus 
administration in the B16 tumor model. ELISpot assays were performed to 
determine the T cell response directed against the virus (immunodominant 
VACV-specific B8R20-27 peptide epitope) (Volz et al. 2018), a non-mutated 
gp100 tumor associated antigen epitope (Hanada et al. 2019), and the tumor 
neoepitope B16-M30 (Kreiter et al. 2015). Injection of WR/TK-/3∆ increased 
T cell reactivity to all the three epitopes (Figure 14), but, of note, we found 
clearly increased levels of epitope specific IFN-γ-producing T cells directed 
against the tumor antigens (gp100 and B16-M30) compared to treatments 















Figure 14. Intratumoral administration of deletion mutant VACV induces 
antitumor T cell responses directed against tumor neo-antigens. 
C57BL/6 mice harbor ing B16 tumors were treated as indicated in Figure 
5 and, 8 days after vi rus administrat ion, splenocytes were prepared, in 
v i tro  st imulated with indicated peptides, and analyzed for IFN -γ 
producing cel ls by ELISPOT. Individual values of IFN-γ spot forming 
cel ls (SPC)/105 splenocytes in 4 -5 mice/group and mean ±SD are 







Although our understanding of cancer biology is constantly growing, cancer 
continues to be a leading cause of death worldwide. Despite the important 
advancements in treating many types of cancer, further research on cancer 
treatments is essential to improve the outcome of cancer patients and to find 
safe and effective therapies for all patients affected by the disease. Cancer 
immunotherapies emerged as a new form of cancer treatment that mobilizes 
the immune system to recognize and attack cancer cells. Several types of 
immunotherapies are used to treat cancer, including immune checkpoint 
inhibitors, T-cell transfer therapy, cancer vaccines, and oncolytic viruses. 
Oncolytic viruses are one form of immunotherapy that utilizes viruses to 
infect and destroy cancer cells. Either naturally or due to genetic 
modifications oncolytic viruses infect, replicate in and kill cancer cells without 
harming healthy cells. Importantly, the virus infection alarms the immune 
system and, if paired with the virus-mediated release of tumor antigens, can 
generate an immune response directed against tumor epitopes. Vaccinia 
virus (VACV), part of the poxvirus family, has served as backbone for the 
successful generation of promising candidates for oncolytic virotherapy 
(Moehler et al. 2019). However, candidate VACV viruses tested to date in 
patients demonstrated a suboptimal capacity to establish antitumor 
immunities (Harrington et al. 2019). 
Why is further research in cancer immunotherapies necessary? 
The immune system is a complex and powerful biological orchestra that not 
only fights off infections but also protects the body from mutated cells. 
Nevertheless, there is a fine balance between burden of cellular mutations 
and the capability of the immune system to destroy such cells, that at some 
point in tumor progression gets lost and the tumor overwhelms the immune 




immune cells to help tumor progression and metastasis, like myeloid-derived 
suppressive cells (MDSCs) (Ouzounova et al. 2017) or tumor-associated 
macrophages (TAMs). TAMs are found in large numbers in breast tumors, 
for example, and are able to actively promote growth and metastasis 
(Williams et al. 2016). However, other immune cells found in the tumors, 
such as tumor-infiltrating lymphocytes (TILs), are a sign that the immune 
system is responding to the tumor and trying to destroy it (Lawson et al. 
2020). A large number of TILs in patients’ tumors is prognostically a good 
sign (Idos et al. 2020; Bremnes et al. 2016; Lee et al. 2008). Despite the 
effort of the immune system to prevent or slow down cancer growth, tumors 
develop mechanisms to avoid either recognition or destruction by the 
immune system (Seliger et al. 2017). Immunotherapies are developed for 
preventing these immune-evading mechanisms, and they demonstrated that 
the capability of the immune system to fight back tumor cells could be 
restored. These therapies focus on stimulating the immune system to better 
fight and recognize tumor cells rather than destroying them directly, like 
chemo- or radiotherapy. One of the main advantages of boosting the 
immune system compared to classical cancer therapy is the prevention of a 
relapse due to the memory function of the adaptive immune system.  
One of the more successful immunotherapies so far are the so-called 
immune checkpoint inhibitors. They harness pre-existing but ineffective 
immune cells and achieve remarkable clinical success across different 
tumor types, including melanoma, non-small-cell lung cancer, urothelial 
carcinoma and Hodgkin's lymphoma with durable objective responses 
(Rosenberg et al. 2016; Garon et al. 2015; Ansell et al. 2014). Remarkable 
clinical results could also be seen in patients suffering from hematologic 
malignancies treated with chimeric antigen receptor (CAR) T-cells. In 
studies on acute lymphoblastic leukemia, complete response (CR) rates of 
70% to 90% could be achieved. Regardless this success in the clinic, there 





toxicity, efficacy, and targeting (Sambi et al. 2019). In the case of CAR T-
cells, for example, the difficulty to find a specific antigen can lead to serious 
side effects after CAR-T cell therapy, including cytokine release syndrome 
(CRS), neurological toxicity, or the attack of non-tumor tissue with different 
severities of side effects (Hartmann et al. 2017; Makita et al. 2017). 
Furthermore, the complex structure of the immunosuppressive tumor 
microenvironment represents a major obstacle for immunotherapies. Up to 
today, they only work on a small subset of cancers and their efficacy highly 
varies between patients (Yang 2015; Nakamura and Smyth 2017). This 
indicates that therapies or combination of therapies that activates more 
robustly antitumor immune responses are needed. The success, but also 
the obstacles, of novel anticancer immunotherapies underlines the 
importance of understanding basic tumor immunology, the complex 
interaction of tumor cells and immune cells and emphasize the power the 
immune system has in the battle against cancer as well as the possibility for 
novel therapeutic options. 
Benefits of oncolytic viruses as immunotherapeutic agents and the 
advantages of poxviruses 
The use of oncolytic viruses (OVs) demonstrated encouraging clinical 
results and to be promising as an immunotherapeutic approach in the field 
of cancer treatment. An appealing feature of OVs is their tumor-specificity, 
supported by the fact that tumor cells favor viral replication due to apoptosis 
resistance, growth suppression and immune evasion strategies, and defects 
in antiviral signaling pathways (Hanahan and Weinberg 2011). What makes 
oncolytic viruses even more attractive is their capability not only to destroy 
tumor cells directly because of viral replication, but also to activate both the 
innate and the adaptive immunity. Oncolytic virus infection triggers a 
signaling cascade culminating in the release of damage-associated 




pattern (PAMPs), which is able to overcome the immunosuppressive milieu 
in the tumor microenvironment (Marelli et al. 2018; Filley and Dey 2017; 
Davola and Mossman 2019). This, together with the release of tumor-
associated antigens (TAAs) due to tumor cell lysis, leads to the activation of 
an innate and adaptive anti-tumor immune response, which is the key in 
oncolytic virotherapy. With increasing recognition of the immune system in 
OV efficacy, “arming” OVs with immunostimulating transgenes is a common 
modification. For example, the addition of granulocyte macrophage colony-
stimulating factor (GM-CSF) to the viral genome, a potent inducer of 
antitumor immunity (Dranoff 2002), recruits antigen-presenting cells (APCs) 
and promotes their maturation while stimulating antitumor immunity 
(Andtbacka et al. 2015; Kemp et al. 2019). 
In the last 20 years, 97 independent clinical trials investigating OVs were 
reported with 11 different viruses, being poxviruses one of the most common 
(12.4%) (Macedo et al. 2020). Within poxviruses, vaccinia virus (VACV) is 
the widest used due to several unique features, which makes it particularly 
attractive for the design of oncolytic viruses: (i) It has a rapid and lytic 
replication cycle and a high degree of tissue destruction (Wein et al. 2003; 
Zeh and Bartlett 2002); (ii) VACV’s excessive use as a live vaccine in the 
smallpox eradication campaign helped to a profound knowledge of VACV 
biology and pathogenesis, as well as to well defined contraindications and 
how to counteract side effects (Fenner et al. 1988; Cono et al. 2003). (iii) It 
is possible to insert large amount of foreign DNA (up to 25 kb) into the large 
double-stranded DNA genome, what makes VACV a promising candidate to 
modulate the TME and enhance its antitumor activity (Smith and Moss 
1983). (iv) The cytoplasmic replicative cycle of VACV prevents integration of 
viral genome into host genome (Moss 2013) (v) Important for the systemic 
delivery, VACV can efficiently spread through the bloodstream and between 
tumors (Kirn et al. 2008; Downs-Canner et al. 2016). (vi) Furthermore, VACV 
infections are highly immunogenic, inducing both humoral and CD4+and 





(Walsh and Dolin 2011). By deleting selected VACV genes it is even 
possible to further increase their immunogenicity (Albarnaz et al. 2018) (vii) 
Finally, oncolytic VACV can replicate selectively in tumor-associated 
endothelial cells, which leads to tumor vessels destruction and vascular 
collapse of the tumor (Hou et al. 2014).  
Several trials investigating oncolytic VACV are currently ongoing (National 
Institute of Health. The clinical trials databases. Available from: 
www.clinicaltrials.gov (accessed:12.02.2021)). Pexastimogene 
devacirepvec (Pexa‐Vec, a thymidine kinase-deleted VACV expressing GM-
CSF) is currently the most advanced oncolytic poxvirus candidate, and it has 
been administrated alone or in combination with sorafenib or immune 
checkpoint inhibitors; it is mainly being assessed for the treatment of 
hepatocellular carcinoma (HCC) in later phase trials. In a randomized phase 
II study of intratumoral Pexa‐Vec, it demonstrated a favorable safety profile, 
with the most common side effects being flu‐like symptoms. A response rate 
of 62% could be achieved after a high dose of Pexa‐Vec and was associated 
with improved overall survival when compared with the low‐dose group 
(Breitbach et al. 2015). Although these promising results in Phase II, an 
oncolytic VACV candidate has not reached yet approval. 
How can the anti-tumor response induced by VACV be improved? 
Despite the tremendous progress made in the design and generation of 
oncolytic viruses, durable clinical responses are rare. In order to revert that, 
further research is ongoing to exploit the potential of VACV as antitumor 
agents. Due to the importance of an anti-tumor immune response, one 
strategy followed to enhance their efficacy is the insertion of transgenes 
encoding for immunostimulatory chemokines or cytokines, being the most 
prominent example GM-CSF or different interleukins (Wang et al. 2017; 
Stephenson et al. 2012). Liu et al demonstrated that arming a tumor-




number of local CD8 T-cell and the induction of a systemic anti-tumor 
immunity, as well as a decrease in different immunosuppression factors, 
leading to an improved therapeutic effect (Liu et al. 2015c).  
Another strategy followed with oncolytic VACV targets the 
immunosuppressive TME. An oncolytic vaccinia virus expressing the PGE2 
inactivating enzyme HPGD was able to significantly reduce levels of 
suppressive MDSC within the tumor and to re-sensitize tumors to viral 
therapy (Hou et al. 2016). As metabolic insufficiencies induced by the tumor 
microenvironment are a barrier due to their inhibition of the effector function 
of T-cells, Rivadeneira et al. demonstrated that the improvement of T-cell 
metabolic function in the tumor microenvironment translates into a better 
therapeutic response. Therefore, they engineered an oncolytic VACV 
delivering the adipokine Leptin, which metabolically reprogrammed T cells 
in order to support antitumor responses (Rivadeneira et al. 2019). 
In our group, we have also attempted a different and novel strategy: 
activation of immunogenic cell death (ICD) after infection of cancer cells. 
Classical mechanisms of cell death, such as apoptosis or autophagy, are 
described as tolerogenic and do not attract or activate immune cells for the 
recognition of antigens codified within the dying cell (Curtin and Cotter 2003, 
Green et al. 2009). Differently, activation of ICD pathways, such as 
necroptosis or pyroptosis, leads to the release of different damage-
associated molecular patterns (DAMPs), which recruit and activate DCs. 
The induction of tumor ICD subsequently leads to a stepwise induction of an 
anti-tumor immune response by enhancing cross-priming of CD8 T-cells 
(Galluzzi et al. 2017). The expression of the necroptosis executioner MLKL 
demonstrated to induce potent antitumor T cell responses directed against 
tumor neo-antigens, which translated into an outstanding antitumor activity 
(Van Hoecke et al. 2020). 





in terms of transiently overcoming the immunosuppressive TME. Yet, data 
from clinical trials make evident that OV-monotherapy is rarely curative, and 
every day it is clearer that tackling cancer from different fronts could be the 
deciding path to success in defeating cancer. The rational combination with 
other forms of cancer treatment like chemotherapy (Ranki et al. 2016), 
radiation therapy (Wilkinson et al. 2016), or other immunotherapies 
(Ottolino-Perry et al. 2015; Ottolino-Perry et al. 2010; Sampath and Thorne 
2015) may be the key for an enhanced immunological effect and durable 
therapeutic responses (Zhang and Cheng 2020). For such combinatory 
immunotherapies, oncolytic VACV are preferential candidates due to their 
low toxicity and combinatory potential, as they have demonstrated 
synergistic effects when combined with several immunotherapies.  
Immune checkpoint inhibitors (ICIs) block the so-called immune checkpoints 
that are expressed by certain types of immune and cancer cells. In regards 
to cancer, those immune checkpoints prevent T cells from killing cancer 
cells. The blockade of these immune checkpoints leads to a re-activation of 
TILs and demonstrated outstanding results in the clinic (Overman et al. 
2017). However, the effect of ICIs depends on the number of immune cells 
within the tumor, and patients that do not respond to ICI normally present 
“cold” tumors, which are characterized by minimal CD8 infiltration (Herbst et 
al. 2014). Oncolytic viruses (OVs) can induce efficient immune infiltration 
and therefore promote the efficacy of ICIs (Sivanandam et al. 2019; Zamarin 
et al. 2018; Liu et al. 2017). Chesney et al evaluated in a randomized phase 
2 study the effect of anti-CTLA4 antibody alone or in combination with T-Vec 
in patients with advanced melanoma. They observed an objective response 
of 39% to the combinational treatment, compared to 18% of ICI alone 
(Chesney et al. 2018). Similar results could be seen when T-Vec was 
combined with an anti-PD1 antibody. The objective response rate (ORR) 
was even 62% and those patients showed an increased level of CD8+T cells 




one has to consider that the effect of ICIs can diminish viral replication, and 
that the success of this combinational therapy depends on the choice of the 
antibody, the viral strain, and, more importantly, the timing of the treatments 
(Rojas et al. 2015). The simultaneous administration of OV and ICI leads to 
an early induction of anti-viral immunity and a decrease of oncolytic activity, 
although this can be solved by a sequential administration of the treatments 
(Rojas et al. 2015).  
The OVs capability to turn “cold” tumors into “hot” tumors can also help to 
overcome the obstacles of CAR T-cell therapy in solid tumors. Combination 
with OV induces synergistic effect thanks to the virus-driven release of 
DAMPs, that can enhance tumor infiltration and persistence of CAR-T cells 
(Ajina and Maher 2017; Ajina and Maher 2019; Rosewell Shaw and Suzuki 
2018). At the end of last year, the first-in-human Phase I trial investigating 
CAR T and OV combination started (NCT03740256).  
Despite the potential of OV in general and VACV in particular, further 
development of novel candidates with increased capacity to robustly activate 
antitumor immune response is needed for exploiting all the potential that 
these agents have for the treatment of nowadays incurables cancers. 
Generation of oncolytic VACV with deletions in immunomodulatory 
proteins inhibiting IRF3 activation in order to increase their potency to 
activate cellular antitumor immunity 
The goal of this work was to obtain a replication-efficient oncolytic VACV 
with improved capacity to activate antitumor T cell responses. The 
replication of oncolytic VACV in cancer cells leads to the release of danger 
associated molecular patterns (DAMPs) together with a multitude of tumor-
specific antigens, turning “cold” tumors into “hot” tumors for more efficacious 
immunotherapy (Shi et al. 2020). The strategy that we followed in this work 





poly(I:C), when used as an adjuvant in cancer vaccination, leads to a Th1 
polarization of the immune response and increases the amount of anti-tumor 
CTLs (Kano et al. 2016), which directly correlates with robust antitumor 
immunity in the clinic (Mikhaylova et al. 2018). As poly(I:C) selectively 
activates TLR3, we attempted to construct an oncolytic vector virus with the 
capacity to activate the TLR3-IRF3 pathway after infection.  
In line with its outstanding capacity to evade antiviral innate immunity, VACV 
encodes for several immunomodulatory proteins directly interfering with the 
host TLR3-IRF3 innate response pathway. To promote the activation of this 
pathway after infection, a series of oncolytic VACV were constructed 
combining the deletion of the thymidine kinase gene (to achieve selective 
replication in cancer cells) with targeted inactivation of selected genes 
interfering with IRF3 pathway activation. The following target proteins were 
chosen due to their important inhibitory mechanisms at different levels in the 
pathway: C10 (also known as C16 due to its nomenclature in the Western 
Reserve strain) prevents dsDNA recognition by DNA-PK (Peters et al. 2013; 
Scutts et al. 2018); N2 interferes by yet unknown mechanisms the 
downstream of phosphorylated IRF3 and its nuclear translocation (Ferguson 
et al. 2013); and C6 interacts with NAP1, TANK, and SINTBAD, the scaffold 
adaptor proteins for the kinases TBK1 and IKKε, that lead to IRF3 activation 
(Unterholzner et al. 2011; Smith 2018). The inactivation of such 
immunomodulatory genes of VACV demonstrated in the past to improve the 
level of CD8 T-cells in the context of vaccination strategies (Sumner et al. 
2013; García-Arriaza et al. 2014). All the possible mutant VACV combining 
deletions in up to three genes were constructed, but one single-, one double-
, and the triple-deleted mutant viruses were selected for complete testing; 
the selection of the candidates for complete testing was performed based 
on the lack of loss in cytotoxicity and in replicative-capacity in vitro (Figure 
9A, 10). Deletions included in the final candidate oncolytic VACV are 




three of these mutations does not impair the capacity of VACV to replicate 
in cancer cells nor their cancer cell-killing efficacy in vitro.  
Combination of deletions in C10L, N2L, and C6L genes results in activation 
of the TLR3-IRF3 pathway as demonstrated by detection of phosphorylated 
IRF3 and interferon-β mRNA (Figure 11, 12). Increasing levels were 
detected by the introduction of deletions in genes interfering with the TLR3-
IRF3 pathway to the genome of the control virus WR/TK-, and Figure 11D 
demonstrates that this activation is mediated by accumulation of such 
deletions rather than by any of the single deletions. In mouse models, this 
TLR3-IRF3 pathway activation translates into improved T cell responses, 
both directed against the virus and the tumor (Figure 15). Importantly, anti-
tumor T cells are directed against tumor associated-antigens (gp100), but 
also against tumor neo-epitopes (B16-M30), and T cell activities elicited by 
the WR/TK-/3Δ are significantly higher than responses obtained with the 
non-treated group. Finally, these enhanced tumor-directed immune 
responses are associated with an improved antitumor activity in two 
syngeneic mouse tumor models (Figure 14), strongly suggesting the 
feasibility and the efficacy of the proposed strategy.  
Previously, an oncolytic VACV expressing TRIF (the main adaptor in the 
TLR3-IRF3 signaling pathway) also explored the strategy of activating the 
TLR3-IRF3 pathway after infection of tumor cells (Rojas et al. 2016). This 
virus demonstrated a switch from a Th2- to a Th1-skewed response and 
displayed enhanced therapeutic activity in mouse models. However, 
replication of the virus was strongly hindered within tumors (using the Renca 
model) due to massive pathway activation; on the contrary, our novel 
strategy of accumulating up to three deletions in VACV genes interfering 
with the TLR3-IRF3 pathway fully conserved the replication capacity in 
Renca tumors (Figure 13). Previously, the importance of VACV replication 





Hoecke et al. 2020), which is in discrepancy to some previous reports (Dai 
et al. 2017). Yet, virus replication leads to tumor cell lysis and release of 
tumor antigens and danger signals, in addition to amplify the initial dose 
administrate. Thus, maintaining an efficient replication in tumor cells is a key 
factor for the outcome of oncolytic therapies and should be an important 
feature when developing a candidate for clinical evaluation.  
Although able to improve antitumor immune responses, levels of 
phosphorylated IRF3 and IFN-β mRNA detected after infection with the 
WR/TK-/3Δ do not reach the levels observed after infection with MVA 
(Figures 11, 12). Previously, VACV incorporating single deletions in the C6L, 
the N2L, or the C10L gene demonstrated enhanced immunogenicity and 
highly reduced virulence in mice (Ferguson et al. 2013; Sumner et al. 2013; 
Fahy et al. 2008). Yet, after infection with any of these three single deleted 
VACV, we did not detect TLR3-IRF3 pathway activation in vitro (Figure 11D). 
We hypothesize that the activation detected in in vitro assays may not 
properly reflect levels of activation in vivo in animal models, and lack of 
activation in tumor cell cultures may not be predictive for stronger activation 
of antitumor immune responses within tumors due to the complexity of tumor 
microenvironment and the diversity of cells present in tumors. 
Future perspectives 
Together, the data here presented demonstrate that it is possible to generate 
an oncolytic VACV with the ability to activate the TLR3-IRF3 pathway while 
maintaining full capacity to productively replicate in cancer cells. Importantly, 
the combination of these features translates into an improved antitumor 
immunity and antitumor efficacy of the oncolytic vector virus. To test the 
possibility to improve this activation, further deletions could be incorporated 
into the WR/TK-/3Δ candidate virus. One possible candidate gene is D10R, 
a de-capping protein, whose deletion has also been described to activate 




constructed a VACV derived from the WR/TK- strain and incorporating a 
single deletion in such gene to test their capacities as an oncolytic. In vitro, 
such virus produced 10 times less progeny virus than its WR/TK- counterpart 
and presented an important reduction in the size of plaques (unpublished 
data). Apparently, the combined deletion of the thymidine kinase and the 
D10R gene compromise the ability of this deletion mutant virus to efficiently 
replicate in cancer cells. Thus, we discarded the D10R deletion for the 
construction of candidate oncolytic viruses due to the reduction of replicative 
capacity in cancer cells. Additional VACV regulatory proteins with inhibitory 
functions in the activation of the TLR3-IRF3 signaling pathway that are 
considered for incorporation into our candidate virus include A46, which 
interacts with TRIF (Fedosyuk et al. 2016), K7, which binds the DEAD-box 
RNA helicase 3 (DDX3) (Schröder et al. 2008), B19 (also known as B18 due 
to its nomenclature in the Western Reserve strain), which is a soluble type I 
interferon receptor (Alcamí et al. 2000), and B2, which encodes a viral 
nuclease with cGAMP-specific activity (Eaglesham et al. 2019). However, 
further deletions incorporated to the WR/TK-/3Δ virus may compromise the 
ability of these deletion mutant viruses to efficiently replicate in cancer cells, 
as demonstrated by the growth deficiency of the natural highly-deleted 
mutant virus MVA, which is unable to replicate in mammalian cells. An 
appropriate balance between the activation of danger signaling pathways 
and virus replication must be found for optimizing oncolytic VACV 
immunotherapies. 
One further advantage of our strategy to activate more robust antitumor 
immunities is its capacity to be combined with other genetic modifications. 
Our candidate deleted VACV can serve as a backbone for incorporating 
transgenes to further improve antitumor immune responses or other aspects 
of the therapy. These transgenes, as discussed earlier, can include 
cytokines or chemokines, genes that target the tumor microenvironment, or 





transgenes simultaneously as deleted genes can serve as insertion loci; 
expression of more than one transgene at the same time can maximize the 
therapy and attack the tumor on different fronts. In addition, the candidate 
VACV can be combined with classical antitumor therapies or novel 
immunotherapies to produce robust responses in patients suffering from a 




VII  SUMMARY  
Characterization of candidate oncolytic vaccinia viruses with 
deletions in viral genes blocking the activation of interferon 
regulatory factor 3 immune signaling. 
Over the last two decades, the understanding of the relationship between 
cancer and the immune system has considerably changed and implemented 
the role of the immune system controlling tumorigenesis and tumor 
progression. Cancer immunotherapies aim to mobilize the immune system 
to kill cancer cells and represent a major progress in cancer therapeutics.  
Robust anti-tumor CTL-responses have demonstrated to play a key role in 
the successful treatment of cancer. In cancer vaccination, the use of Poly 
I:C, a TLR3 agonist, as an adjuvant has demonstrated to increase the 
number of CTLs targeting tumor antigens. TLR3 signaling culminates in 
IRF3 phosphorylation and consequently expression of type I interferons 
(IFN). As type I IFNs also play a crucial role in anti-VACV defense, VACV 
encode several proteins (including C10, N2 or C6) that antagonize the TRL3-
IRF3 signaling pathway at different levels, efficiently inhibiting 
phosphorylation of IRF3. However, deletions in some of these genes, such 
as C6 or N2, demonstrated to improve CD8 T-cell responses in vaccination. 
MVA (Modified Vaccinia virus Ankara), a highly attenuated strain of VACV 
with genomic mutations and deletions that inactivate many 
immunomodulatory genes, can robustly induce the secretion of type I IFN 
after infection. Nevertheless, due to MVA’s defective replication in 
mammalian cells, its capacity for usage as an oncolytic agent is greatly 
reduced. Thus, the generation of oncolytic VACV combining the capacity to 
activate the TLR3-IRF3 pathway with an efficient replication in cancer cells 
represents a major step towards an efficient VACV-based oncolytic therapy.  





deletions in key VACV genes involved in the inhibition of IRF3 activation. 
We evaluated their replication competence as well as their ability to elicit T-
cell responses against tumor neo-antigens and their antitumor activity. The 
removal of up to three key genes (C10L, N2L, and C6L) from VACV genome 
did not reduce the strength of viral replication, both in vitro and in vivo, but 
resulted in the rescue of IRF3 phosphorylation upon infection of cancer cells. 
Importantly, when tested in syngeneic mouse tumor models, this activation 
translated into enhanced CTL responses directed against tumor associated 
antigens and neo-epitopes, and a greatly improved antitumor activity. We 
demonstrated the feasibility to obtain replication efficient VACV with 
increased capacity to activate the IRF3 pathway. Moreover, the candidate 
triple deletion-mutant virus represents an excellent basis for future 
preclinical and potential clinical studies in cancer virotherapy. Hereby, 
development and application of such oncolytic VACV to treat cancers in 
clinical veterinary medicine appear promising to further assess the potential 




VIII  ZUSAMMENFASSUNG 
Charakterisierung onkolytischer Vacciniaviren mit Deletionen 
in viralen Genen zur Blockade der Aktivierung des Interferon 
Regulatory Factor 3 Signalweges 
In den letzten 20 Jahren hat sich das Verständnis der Beziehung zwischen 
dem Immunsystem und Krebs grundlegend geändert und dem 
Immunsystem wurde eine neue Rolle in Bezug auf Tumorgenese und 
Tumorprogression zugesprochen. Krebsimmuntherapien zielen darauf ab 
das Immunsystem zu mobilisieren, um Krebszellen zu zerstören und stellen 
eine Revolution in der Krebsbehandlung dar.  
Robuste anti-tumor T-Zell-Antworten haben sich als Schlüsselrolle in der 
erfolgreichen Behandlung von Tumoren erwiesen. Bei der Krebsimpfung hat 
die Verwendung des Toll-Like-Rezeptor 3 (TLR3)-Agonisten Poly-I:C als 
Adjuvant zu einem Anstieg der Zahl der gegen Tumorantigene gerichteten 
zytotoxischen T-Zellen (CTL) geführt. Eine TLR3-Aktivierung führt zu einer 
Verstärkung der Expression von Typ 1 Interferonen (IFN), welche direkt mit 
der Zahl der CTL korreliert. VACV kodieren für verschiedene Proteine 
(einschließlich C10, N2 oder C6), die diesen TLR3-IFN-Signalweg auf 
mehreren Ebenen antagonisieren und so eine Phosphorylierung und 
Aktivierung des zentralen Transkriptionsfaktors Interferon Regulatory Factor 
3 (IRF3) verhindern. Die Herstellung und Untersuchung von VACV 
Deletionsmutanten mit der Fähigkeit den TLR3-IRF3 Signalweg zu 
aktivieren und sich gleichzeitig effizient in Krebszellen zu vermehren, stellt 
einen vielversprechenden Schritt in Richtung einer wirksamen VACV-
basierenden onkolytischen Therapie dar.  
In dieser Arbeit wurden eine Reihe onkolytischer Testviren konstruiert, 
indem im VACV-Genom Deletionen in Schlüsselgenen, welche eine IRF3-





Charakterisierung der Viren beinhaltet die Überprüfung der 
Replikationskompetenz in Krebszellen, die Fähigkeit eine gegen Tumor-
Neoantigene gerichtete T-Zellantwort auszulösen und deren 
Antitumoraktivität im präklinischen Modell. Eine Deletion von bis zu drei 
Schlüsselgene (C10L, N2L und C6L) aus dem Genom von VACV führte 
nicht zu einer reduzierten Replikationsfähigkeit, weder in vitro noch in vivo, 
jedoch aber zur Phosphorylierung und Aktivierung des Transkriptionsfaktors 
IRF3 bei der Infektion von Krebszellen. In syngenen Maus-Tumormodellen 
konnte eine verstärkten CTL Antwort induziert werden, die gegen 
tumorassoziierte Antigene und Neoepitope gerichtet war und mit einer 
erheblich verbesserten Antitumoraktivität assoziiert war. Damit konnte 
gezeigt werden, dass es möglich ist, ein vollständig vermehrungsfähiges 
und den IRF3 Signalweg aktivierendes VACV herzustellen und erfolgreich 
einzusetzen. Das in dieser Arbeit beschriebene neue Testvirus mit 
dreifacher Deletion bietet nun eine hervorragende Grundlage für zukünftige 
präklinische und potenzielle klinische Studien in der experimentellen 
Krebstherapie dar. Dabei erscheint die Entwicklung und Anwendung eines 
solchen onkolytischen VACV zur Behandlung von Krebserkrankungen in der 
klinischen Veterinärmedizin besonders vielversprechend, um das Potenzial 
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1. Consumables/plasticware, reagents, chemicals 
Describtion Supplier 
6-/24-/96-well flat bottom plates  Sarstedt, Nümbrecht, Germany 
Cell culture flasks (25/75/175 cm2) Sarstedt, Nümbrecht, Germany 
Serological pipettes (5/10/25 ml) Sarstedt, Nümbrecht, Germany 
Reagent reservoir Fisher Scientific, Waltham, USA 
Micro tubes 1,5ml Sarstedt, Nümbrecht, Germany 
Micro tubes, safe seal, 2ml Sarstedt, Nümbrecht, Germany 
Falcon (10ml/50ml) Sarstedt, Nümbrecht, Germany 
ep Dualfilter T.I.P.S.®, 10µl/100µl Eppendorf AG, Hamburg, 
Germany 
Biosphere® Filter Tips 
(20µl/100µl/200µl/1000µl) 
Sarstedt, Nümbrecht, Germany 
Eppendorf PCR tubes Eppendorf AG, Hamburg, 
Germany 
TUBES UC 1 X 3-1/2 Beckman Coulter, Brea, USA 
Petri dishes SIGMA-ALDRICH, St. Louis, 
USA 
Luer eccentric tip VWR, Radnor, USA 
Falcon cell strainer, Falcon® A Corning Brand, Corning, USA 
Spectrum Labs™ MICROKROS 
HOLLOW FIBER FILTER MODULE 
1XFL PS 0.05 
Fisher Scientific, Waltham, USA 
Syringe PP/PE, without needle SIGMA-ALDRICH, St. Louis, 
USA 
Disposable syringe Omnican Fisher Scientific, Waltham, USA 
Blotting-Membranen, Amersham™ 
Protran™ Premium 0.2µm NC 
GE Healthcare Life Science, 
Chicago, USA 
Western Blotting Filter Paper  Fisher Scientific, Waltham, USA 
Mini-PROTEAN® TGX™ Gels Bio-Rad, Hercules, USA 
BSA SIGMA-ALDRICH, St. Louis, 
USA 
Precision Plus Protein™ Dual Color 
Standard 
Bio-Rad, Hercules, USA 
1 kb DNA ladder New England Biolabs, Ipswich, 
USA 





OneTaq® 2x Master Mix New England Biolabs, Ipswich, 
USA 
Lipofectamine 2000 Fisher Scientific, Waltham, USA 
4X Laemli sample buffer Bio-Rad, Hercules, USA 
Blue Juice Gel loading buffer Life Technologies, Carlsbad, 
USA 
Red Blood Cell Lysis buffer SIGMA-ALDRICH, St. Louis, 
USA 
Phorbol myristate acetat SIGMA-ALDRICH, St. Louis, 
USA 
Ionomycin  SIGMA-ALDRICH, St. Louis, 
USA 
TAE buffer 50X Fisher Scientific, Waltham, USA 
10X Tris/Glycine/SDS Bio-Rad, Hercules, USA 
Trypan Blue SIGMA-ALDRICH, St. Louis, 
USA 
OneShot™Top10 Fisher Scientific, Waltham, USA 
Ampicillin, sodium salt Life Technologies, Carlsbad, 
USA 
Crystal violet SIGMA-ALDRICH, St. Louis, 
USA 
Benzonase VWR, Radnor, USA 
Carboxymethylcellulose sodium salt, 
low viscosity 
SIGMA-ALDRICH, St. Louis, 
USA 
Sucrose SIGMA-ALDRICH, St. Louis, 
USA 
RIPA buffer Abcam, Cambridge, UK 
Half™ Protease & Phosphatase 
Inhibitor Cocktail 
Fisher Scientific, Waltham, USA 
Isofluran CP®  cp-pharma, Burgdorf, Germany  
Tween®20 Promega, Madison, USA 
LE Agarose Biozym, Hessisch Oldendorf, 
Germany 
2-Mercaptoethanol Carl-Roth GmbH, Karlsruhe, 
Germany 
Hydrochloride acid (HCl) Carl-Roth GmbH, Karlsruhe, 
Germany 




Methanol (CH4O) Carl-Roth GmbH, Karlsruhe, 
Germany 
Sodium chloride (NaCl) Carl-Roth GmbH, Karlsruhe, 
Germany 
Tris ultrapure (C4H11NO3) AppliChem, Darmstadt, 
Germany 
Glycin (C2H5NO2) AppliChem, Darmstadt, 
Germany 
PBS In-house production, LMU, 
München, Germany 
Distilled water In-house production, LMU, 
München, Germany 
2. Buffers, solutions 
Buffers, solutions Conditions 
TBS 10X (pH 7,4) 200 mM Tris base  
1.4 M NaCl  
distilled water 
Transfer buffer 1X 25 mM Tris base  
200 mM glycine  
20% methanol  
distilled water 
1M Tris-HCl (pH 8) 1 M Tris base 
distilled water 
3. Commercial kits 
Describtion Supplier 
Plasmid Plus Maxi Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick PCR purification Kit Qiagen, Hilden, Germany 
QIAamp DNA Mini Kit Qiagen, Hilden, Germany 
RNeasy Plus Mini Kit Qiagen, Hilden, Germany 
Omniscript RT Kit Qiagen, Hilden, Germany 
Spin Miniprep Kit  Qiagen, Hilden, Germany 
Quick Ligation Kit  New England Biolabs, Ipswich, 
USA 





Pierce ECL Plus Western Blotting 
substrate 
Fisher Scientific, Waltham, USA 
CellTiter96® Aqueous Non-
radioactive cell proliferation assay 
Promega, Madison, USA 
Mouse IFN-γ ELISPOT MABTECH, Stockholm, Sweden 
4. Laboratory equipment and software 
Equipment Supplier 
Eppendorf Research Plus 
(10µl/100µl/1000µl/12-channel 
300µl) 
Eppendorf AG, Hamburg, 
Germany 
Eppendorf Reference 2 Eppendorf AG, Hamburg, 
Germany 
Thermo Scientific ™ Pipet filler S1 Fisher Scientific, Waltham, USA 
Safety Work Bench BDK-SK 1200 BDK, Sonnenbühl, Germany 
Heraeus HERAsafe Heraeus, Hanau, Germany 
Heraeus Kendro HeraCell 150 CO2 
Inkubator 
Heraeus, Hanau, Germany 
C24 Incubator Shaker New Brunswick Scientific, 
Edison, USA 
Neubauer chamber, improved 
BLAUBRAND® 
BRAND GMBH + CO KG, 
Wertheim, Germany 
Mini Vortex Mixer Fisher Scientific, Waltham, USA 
Corning® LSE™ single block SIGMA-ALDRICH, St. Louis, 
USA 
Sonoplus  Bandelin electronics, Berlin, 
Germany 
Olympus CKX41 Olympus Life Sciences, 
Hamburg, Germany 
Inverted microscope MBL3200 Krüss, Hamburg, Germany 
Mini-PROTEAN® Tetra vertical 
electrophoresis cell 
Bio-Rad, Hercules, USA 
Power Pac 200 Bio-Rad, Hercules, USA 
Trans Blot® Turbo™ Transfer 
System 
Bio-Rad, Hercules, USA 




ChemiDoc™MP Bio-Rad, Hercules, USA 
Sunrise™ Tecan Trading AG, Männedorf, 
Switzerland 
A.EL.VIS Eli.Scan A.EL.VIS, Hannover, Germany 
Mupid®-One Electrophoresis Unit Mupid, Dubai 
TissueLyser II Quiagen, Hilden, Germany 
Hettich Zentrifuge EBA 12R Hettich, Tuttlingen, Germany 
Eppendorf Centrifuge 5810R Eppendorf AG, Hamburg, 
Germany 
OptimaTM LE-80K Ultracentrifuge Beckman Coulter, Brea, USA 
NanoDrop® ND-1000 PEQLAB Biotechnology GmbH, 
Erlangen, Germany 
UV Transilluminator UVP, Upland, USA 
Hanna Checker® pH meter SIGMA-ALDRICH, St. Louis, 
USA 
Navigator™  OHaus, Parsippany, USA 
Caliper, stainless steel Fisher Scientific, Waltham, USA 
Aesculap clipper Isis B. Braun, Melsungen, Germany 
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